Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(14S)-hydroperoxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid + ?
(13S,14S)-epoxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid
-
-
-
?
(16(R),5Z,8Z,11Z,14Z)-16-fluoroeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 78% of the 15,16(R) product and 22% of the 12,16(R) product
-
?
(16(R),5Z,8Z,11Z,14Z)-16-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme and mutant enzyme I593A prouce small amounts of unspecific products. Mutant enzyme F353L produces 6% of 15,16(R) product and 94% of the 12,16(R) product
-
?
(16(S),5Z,8Z,11Z,14Z)-16-fluoroeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 69% of the 15,16(S) product and 31% of the 12,16(S) product
-
?
(16(S)5Z,8Z,11Z,14Z)-16-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 93% of the 15,16(S) product and 7% of the 12,16(S) product
-
?
(17(R),5Z,8Z,11Z,14Z)-17-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 1% of the 15,17(R) product and 99% of the 12,17(R) product
-
?
(17(S),5Z,8Z,11Z,14Z)-17-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
-
wild-type enzyme: 3% of the 15,17(S) product and 97% of the 12,17(S) product
-
?
(18(R),5Z,8Z,11Z,14Z)-18-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
oxygenation proceeds with little if any enantioselectivity
-
-
?
(18(S),5Z,8Z,11Z,14Z)-18-hydroxyeicosa-5,8,11,14-tetraenoic acid + O2
?
oxygenation proceeds with little if any enantioselectivity
-
-
?
1,2-diarachidonoylglycerophosphocholine + O2
?
1-linoleoyl lysophosphatidic acid + O2
(S)-hydroperoxy 1-linoleoyl lysophosphatidic acid
-
i.e. linoleoyl-lysoPA
major product
-
?
1-linoleoyl lysophosphatidylcholine + O2
(S)-hydroperoxy 1-linoleoyl lysophosphatidylcholine
-
i.e. linoleoyl-lysoPC
major product
-
?
1-palmitoyl-2-arachidonyl phosphatidyl choline + O2
15S-HpETE + ?
-
-
-
?
1-palmitoyl-2-docosahexaenoyl phosphatidyl choline + O2
17S-HpDHE + ?
-
-
-
?
1-palmitoyl-2-eicosapentaenoyl phosphatidyl choline + O2
15S-HpEPE + ?
-
-
-
?
1-palmitoyl-2-linoleoyl phosphatidyl choline + O2
13S-HpODE + ?
-
-
-
?
1-stearoyl-2-arachidonoyl glycerol + O2
15-HETE + ?
-
-
-
?
1-stearoyl-2-linoleoyl glycerol + O2
13S-HPODE + ?
-
-
-
?
11,14,17-eicosatrienoic acid + O2
15-hydroperoxy-11,13,17-eicosatrienoic acid
-
-
-
?
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid + O2
(11S)-hydroperoxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid + (14S)-hydroperoxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid + (17S)-hydroperoxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid
-
-
-
?
5S,15S-dihydroperoxyeicosatetraenoic acid + O2
lipoxin B4
-
-
-
?
5S-hydroperoxy-6E,8Z,10E,14Z-eicosatetraenoic acid + O2
5S,12S-dihydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid
-
-
-
?
5S-hydroperoxy-6E,8Z,10E,14Z-eicosatetraenoic acid + O2
5S,12S-dihydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid + 5S,15S-dihydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid
-
-
-
?
5S-hydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid + O2
5S,12S-dihydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid
-
-
-
?
5S-hydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid + O2
5S,12S-dihydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid + 5S,15S-dihydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid
-
-
-
?
5S-hydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid + O2
5S,15S-dihydroxy-6E,8Z,10E,14Z-eicosatetraenoic acid
-
-
-
?
8,11,14-eicosatrienoic acid + O2
15-hydroperoxy-8,11,13-eicosatrienoic acid
-
-
-
?
alpha-linoleic acid + O2
?
72% activity compared to arachidonate
-
-
?
alpha-linolenate + O2
(9Z,11E,13S,15Z)-13-hydroperoxyoctadeca-9,11,15-trienoic acid + (9Z,11E,13S,15Z)-13-hydroxyoctadeca-9,11,15-trienoic acid
arachidonate + O2
(5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate
arachidonate + O2
(5Z,8Z,11Z,13E)-(12S)-12-hydroperoxyicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-12-hydroperoxyicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
arachidonate + O2
(5Z,8Z,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
ratio of (5Z,8Z,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate to (5Z,8Z,11Z,13E,15R)-15-hydroperoxyicosa-5,8,11,13-tetraenoate is 92:8
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
-
-
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid + (12S,5Z,8Z,10E,14Z)-12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid
arachidonic acid + O2
13-hydroperoxyeicosatetraenoic acid + (5Z,8Z,11R,12E,14Z)-11-hydroperoxyicosa-5,8,12,14-tetraenoic acid + (5Z,8E,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
arachidonic acid + O2
15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid
-
-
-
-
?
arachidonic acid + O2
?
-
-
-
-
?
cholesteryl arachidonate + O2
15S-HpETE + ?
-
-
-
?
cholesteryl linoleate + O2
13S-HpODE + ?
-
-
-
?
cholesteryl linolenate + O2
13S-HpOTE + ?
-
-
-
?
dihomo-gamma-linolenic acid + O2
?
44% activity compared to arachidonate
-
-
?
dilinoleoyl phosphatidic acid + O2
(S)-hydroperoxy dilinoleoyl phosphatidic acid
-
i.e. dilinoleoylPA
-
-
?
dilinoleoyl phosphatidylcholine + O2
(S)-hydroperoxy dilinoleoyl phosphatidylcholine
-
i.e. dilinoleoylPC
-
-
?
docosahexaenoic acid + O2
?
72% activity compared to arachidonate
-
-
?
eicosadienoic acid + O2
?
33% activity compared to arachidonate
-
-
?
eicosapentaenoic acid + O2
15-hydroxyeicosapentaenoic acid
-
-
-
-
?
eicosapentanoic acid + O2
?
61% activity compared to arachidonate
-
-
?
eicosatrienoic acid + O2
?
-
-
-
-
?
gamma-linolenic acid + O2
?
44% activity compared to arachidonate
-
-
?
linoleate + O2
(9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate
-
-
-
-
?
linoleate + O2
(9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoate
-
-
-
?
linoleate + O2
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate + (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoate + (9R,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoate
linoleate + O2
?
-
-
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate
linoleic acid + O2
13(S)-hydroxyoctadecadienoic acid
-
-
12/15LO eicosanoid products reduce cholesterol efflux to high density lipoproteins, regulate ATP-binding cassette transporter G1 expression and enhance ATP-binding cassette transporter G1 degradation and ATP-binding cassette transporter G1 serine phosphorylation
-
?
linoleic acid + O2
13-hydroperoxy-(9Z,11E)-linoleic acid
linoleic acid + O2
13-hydroxylinoleic acid
linoleic acid + O2
13-hydroxyoctadecadienoic acid
-
-
-
-
?
linoleic acid + O2
13-S-hydroxyoctadecadienoic acid
-
both 15-LOX-1, 15-LOX-2 reacts with linoleic acid poorly
-
-
?
linolenate + O2
11-hydroperoxyoctadecatrienoic acid + 9-hydroperoxyoctadecatrienoic acid + 13-hydroperoxyoctadecatrienoic acid
lipoic acid + O2
?
-
-
-
-
r
additional information
?
-
1,2-diarachidonoylglycerophosphocholine + O2
?
-
-
-
?
1,2-diarachidonoylglycerophosphocholine + O2
?
-
-
-
?
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
-
-
(5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate slightly increases expression of monocyte chemoattractant protein MCP-1 in macrophages, also but more potent by 12(S)-hydroxyeicosatetranoic acid, overview, i.e. 15(S)-HPETE and 15(S)-HETE, the first is the predominant product
-
?
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
-
-
(5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate slightly increases expression of monocyte chemoattractant protein MCP-1 in macrophages, also but more potent by 12(S)-hydroxyeicosatetranoic acid, overview, i.e. 15(S)-HPETE and 15(S)-HETE, the first is the predominant product
-
?
alpha-linolenate + O2
(9Z,11E,13S,15Z)-13-hydroperoxyoctadeca-9,11,15-trienoic acid + (9Z,11E,13S,15Z)-13-hydroxyoctadeca-9,11,15-trienoic acid
-
-
-
?
alpha-linolenate + O2
(9Z,11E,13S,15Z)-13-hydroperoxyoctadeca-9,11,15-trienoic acid + (9Z,11E,13S,15Z)-13-hydroxyoctadeca-9,11,15-trienoic acid
-
-
-
?
arachidonate + O2
(5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
671247, 672376, 672543, 672899, 672902, 673030, 675201, 675909, 676263, 676923, 676925, 676927, 677239, 685266, 685525, 685526, 685584, 686173, 687052, 687235, 688159, 688509, 688751, 712712 -
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
and small amounts of (5Z,8Z,10E,14Z)-12-hydro(pero)xy-5,8,10,14-icosatetraenoic acid
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid + 15-hydroxy-5,8,11,13-eicosatetraenoic acid
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
formation of 15S-hydroxyeicosatetraenoic acid and 12S-hydroxyeicosatetraenoic acid in a ratio of 12:1, double oxygenation products 14R,15S-dihydroxyeicosatetraenoic acid and various 8,15-dihydroxyeicosatetraenoic acids are also produced
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
ratio of 15-lipoxygenation to 12-lipoxygenation is 9:1 for the wild-type enzyme and the mutant enzymes V104I, L397M and Q431R. The ratio of 15-lipoxygenation to 12-lipoxygenation is 1:1 for the mutant enzymes V104/L397M/M418V/Q431R, L397M/M418V/Q431R, L397M/M418V and M418V
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
15-hydroxyeicosatetraenoic acid and 12-hydroxyeicosatetraenoic acid in a ratio of 8.6:1
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
further metabolized to (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate, 15-HETE, has no effect on the spontaneous and lipopolysaccharide-stimulated growth of leukemic blasts
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
the bifunctional enzyme also forms (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate, the product of 12-LO activity, EC 1.13.11.31, in a ratio of 9:1 15(S)-HPETE to 12(S)-HPETE, further reduced to the correspondent (S)-hydroxy fatty acids, in eosinophils, overview, the bifunctional enzyme also forms (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate, the product of 12-LO activity, EC 1.13.11.31, in a ratio of 9:1 15(S)-HPETE to 12(S)HPETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
is further metabolized to (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells, it could be a suppressor of prostate cancer development, which functions by restricting cell cycle progression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
catalyzes enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is implicated in inflammatory disorders, 15-lipoxygenase is induced in atherosclerosis and can oxidize low-density lipoprotein to its atherogenic form
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
alternative splicing of 15S-lipoxygenase provides a further level of regulation of fatty acid metabolism
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
12/15LO protein levels and activity are increased in pathologically affected regions of Alzheimers disease brains, enzyme inhibition causes a decrease in amyloid-beta protein, 12/15LO influences amyloid-beta protein precursor protein metabolism, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
15-lipoxygenase type-1 is a prooxidant enzyme, which is expressed in asthmatic lungs leading to formation of pro- and anti-inflammatory mediators, overview
the product is further metabolized to 15(S)-hydroxyeicosatetranoic acid and 15-ketoeicosatetraenoic acid, the latter is the main product, pathway and mechanism, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
15-LOX2 in NHP cells is positively regulated by Sp1 and negatively regulated by Sp3, but 15-LOX2 expression in NHP cells is not directly regulated by androgen/androgen receptor, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
arachidonic acid is metabolized by the 15-lipoxygenase-1 pathway to the vasodilatory eicosanoids hydroxyepoxyeicosatrienoic acid and trihydroxyeicosatrienoic acid
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
arachidonic acid metabolization by lipoxygenases, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is involved in acetylsalicylic acid-triggered production of 15(S)-hydroxyeicosatetranoic acid, 15(S)-HETE, in sensitive asthmatic patients, acetylsalicylate-tolerant asthma patients show reduced 15-LO activity
is metabolized to 15(S)-hydroxyeicosatetranoic, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme modifies high density lipoprotein 3, the major and most antiatherogenic HDL subfraction, and impairs anti-inflammatory activity of the lipoprotein, which, after modification, fails to inhibit TNFalpha-mediated mRNA and protein induction of adhesion molecules and monocyte chemoattractant protein-1, MCP-1, in endothelial cells, overview
is metabolized to 15(S)-hydroxyeicosatetranoic, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
immunohistochemic assay
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
preferred substrate of isozyme 15-hLO-2, reaction of EC 1.13.11.33
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
regioselective oxidation is achieved through control over the position of hydrogen atom abstraction by the geometry and size of the enzyme active site and through control by the protein over the interaction of molecular oxygen with the generated delocalized substrate radical, analysis of catalytic mechanisms of lipoxygenases using 10,10-dideuterated arachidonic acid, 13,13-dideuterated arachidonic acid, and 0,10,13,13-d4-AA, overview
isozymes 15-hLO-1 and 15-hLO-2 also form small amounts of 11-HPETE, 8-HPETE, and 12-HPETE, the rate of 8/12-HPETE production by isozyme 15-hLO-1 with 13,13-dideuterated arachidonic acid as substrate is exeptionally high with 75% of overall production, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
and nonenzymatic production of 15-hydroxy-5,8,11,13-eicosatetraenoic acid, 15-keto-5,8,11,13-eicosatetraenoic acid, 13-hydroxy-14,15-epoxy-5,8,11-eicosatrienoic acid and 11,14,15-trihydroxy-5,8,12-eicosatrienoic acid
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
is further metabolized by hydroperoxide isomerase to the acid-sensitive metabolite 15(S)-hydroxy-11,12-epoxyeicosatrienoic acid, which is hydrolyzed to 11,12,15-trihydroxyeicosatrienoic acid, by a soluble epoxid hydrolase, causing endothelium-dependent smooth muscle hyperpolarization and relaxations, mass spectrometrical metabolite analysis and pathway, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
catalyzes enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
first step in biotransformation of arachidonic acid to the 15-series of leukotrienes, reaction is involved in inactivation of slow-reacting substrances of anaphylaxis
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
high oxygen affinity is important for effective catalysis, L367 is involved in oxygen access, channel structure, overview, arachidonic acid closes the substrate-binding pocket for oxygen diffusion but opens a fourth oxygen access channel
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
15-H(p)ETE is the major reaction product of 15-LOX-2 and 12/15-LOX independent of the pH
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
product ratio is 9 to 1
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
5fold higher affinity for arachidonic acid than for linoleic acid for 15-hLO-1
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
both 15-LOX-1 and -2
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
main product is 12(S)-hydroxyeicosatetranoic acid
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
15-H(p)ETE is the major reaction product independent of the pH
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
H2QBX9
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
12/15LO eicosanoid products reduce cholesterol efflux to high density lipoproteins, regulate ATP-binding cassette transporter G1 expression and enhance ATP-binding cassette transporter G1 degradation and ATP-binding cassette transporter G1 serine phosphorylation
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
-
the mutant enzyme A416G converts arachidonic acid to (11R)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid and (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid in a 1.5:1 ratio
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
-
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
an atomic-level study of the binding modes of linoleic acid to rabbit reticulocyte 15-rLO-1 is presented. Results are compared with binding of arachidonic acid to 15-rLO-1. Linoleic acid seems to adapt more easily to the enzyme structure and differs from arachidonic acid on some dynamical aspects that could introduce kinetic differences, as observed experimentally
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
-
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid + (12S,5Z,8Z,10E,14Z)-12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid
-
93% (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid and 7% (12S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid + (12S,5Z,8Z,10E,14Z)-12-hydroperoxyeicosa-5,8,10,14-tetraenoic acid
-
-
the ratio of (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid to (12S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid is 20 for the wild-type enzyme
-
?
arachidonic acid + O2
13-hydroperoxyeicosatetraenoic acid + (5Z,8Z,11R,12E,14Z)-11-hydroperoxyicosa-5,8,12,14-tetraenoic acid + (5Z,8E,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
-
-
-
?
arachidonic acid + O2
13-hydroperoxyeicosatetraenoic acid + (5Z,8Z,11R,12E,14Z)-11-hydroperoxyicosa-5,8,12,14-tetraenoic acid + (5Z,8E,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
-
-
-
?
linoleate + O2
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate + (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoate + (9R,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoate
-
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate is the primary product
-
?
linoleate + O2
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate + (9Z,11E,13S)-13-hydroperoxyoctadeca-9,11-dienoate + (9R,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoate
-
(9Z,11R,12Z)-11-hydroperoxyoctadeca-9,12-dienoate is the primary product
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
-
reaction of EC 1.13.11.12
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
-
-
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
-
preferred substrate of isozyme 15-hLO-1, reaction of EC 1.13.11.12
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
78% activity compared to arachidonate
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate
-
-
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate
-
-
-
-
?
linoleic acid + O2
13-hydroperoxy-(9Z,11E)-linoleic acid
-
-
-
-
?
linoleic acid + O2
13-hydroperoxy-(9Z,11E)-linoleic acid
-
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
13-hydroperoxy-9,11-octadecadienoic acid + 13-hydroxy-9,11-octadecadienoic acid
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
-
-
-
-
?
linoleic acid + O2
?
-
-
-
-
?
linoleic acid + O2
?
-
-
-
-
?
linoleic acid + O2
?
-
4% of the activity with arachidonate
-
-
?
linoleic acid + O2
?
-
-
-
-
?
linoleic acid + O2
?
-
-
-
-
?
linoleic acid + O2
?
-
reaction of EC 1.13.11.12
-
-
?
linoleic acid + O2
?
-
an atomic-level study of the binding modes of linoleic acid to rabbit reticulocyte 15-rLO-1 is presented. Results are compared with binding of arachidonic acid to 15-rLO-1. Linoleic acid seems to adapt more easily to the enzyme structure and differs from arachidonic acid on some dynamical aspects that could introduce kinetic differences, as observed experimentally
-
-
?
linolenate + O2
11-hydroperoxyoctadecatrienoic acid + 9-hydroperoxyoctadecatrienoic acid + 13-hydroperoxyoctadecatrienoic acid
-
-
-
?
linolenate + O2
11-hydroperoxyoctadecatrienoic acid + 9-hydroperoxyoctadecatrienoic acid + 13-hydroperoxyoctadecatrienoic acid
-
-
-
?
additional information
?
-
incubation of the enzyme with [(11S)-2H]-linoleic acid leads to the formation of hydroperoxides that have lost the deuterium label, thus suggesting that LOX2 catalyzes antarafacial oxygenation as opposed to the mechanism of manganese lipoxygenase
-
-
?
additional information
?
-
incubation of the enzyme with [(11S)-2H]-linoleic acid leads to the formation of hydroperoxides that have lost the deuterium label, thus suggesting that LOX2 catalyzes antarafacial oxygenation as opposed to the mechanism of manganese lipoxygenase
-
-
?
additional information
?
-
-
the enzyme may be involved in the development of atherosclerosis
-
-
?
additional information
?
-
-
15-LOX2 and 15-LOX2sv-b suppress prostate tumor development, and the tumor-suppressive functions apparently do not necessarily depend on arachidonic acid-metabolizing activity and nuclear localization
-
-
?
additional information
?
-
15-LOX2 is a functional tumor suppressor that regulates prostate epithelial cell differentiation, senescence, and growth size, overview
-
-
?
additional information
?
-
-
15-LOX2 is a functional tumor suppressor that regulates prostate epithelial cell differentiation, senescence, and growth size, overview
-
-
?
additional information
?
-
-
eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in eosinophils and mast cells, metabolism of 14,15-leukotrienes in eosinophils, overview
-
-
?
additional information
?
-
a bifunctional enzyme exhibiting 12-LO and 15-LO activity
-
-
?
additional information
?
-
-
a bifunctional enzyme exhibiting 15-lipoxygenase and 12-lipoxygenase, EC 1.13.11.31, activities
-
-
?
additional information
?
-
-
conjugated linoleic acids are no substrates for 15-LO-1 in vitro, overview
-
-
?
additional information
?
-
-
product distributions of lipoxygenases under various conditions, overview
-
-
?
additional information
?
-
-
substrate specificity of 15-hLO isozymes, the specific activity is affected by cholate and lipoxygenation reaction products, e.g. 13-hydroperoxyoctadienoic acid changes the (kcat/Km)AA/(kcat/Km)LA ratio more than 5fold for 15-hLO-1 and 3fold for 15-hLO-2, while 12-(S)-hydroperoxyeicosatetraenoic acid affects only the ratio of 15-hLO-1 more than 5fold. In addition, 13-(S)-hydroxyoctadecadienoic acid and 12-(S)-hydroxyeicosatetraenoic acid also affect substrate specificity, indicating that iron oxidation is not responsible for the change in the (kcat/Km)AA/(kcat/Km)LA ratio, residues R402, F414, F352, I417, and M418 are located at the active site and involved in catalysis, presence of a product-activated, allosteric regulatory site for both 15-hLO isozymes, competitive substrate capture experiments, overview
-
-
?
additional information
?
-
-
15-LOX-2 does not oxygenate (5Z,8Z,11Z,14Z)-nonadeca-5,8,11,14-tetraene-1,19-dioic acid at various pH
-
-
?
additional information
?
-
-
15LO1 interacts with PEBP1 (phosphatidylethanolamine-binding protein)
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type subject produces 21% 12-hydroperoxyicosatetraenoate and 79% 15-hydroperoxyicosatetraenoate
-
-
?
additional information
?
-
15-LOX is a non-heme iron-containing dioxygenase that oxygenates polyunsaturated fatty acids (PUFA) containing cis,cis-1,4-pentadiene moieties
-
-
?
additional information
?
-
human 15-LOX type 1 (ALOX15) is a predominantly 15-lipoxygenating enzyme, which produces only little amounts of (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate (ratio of 9:1)
-
-
?
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation. Intraenzyme oxygen movement
-
-
?
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation. Intraenzyme oxygen movement
-
-
?
additional information
?
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification
-
-
?
additional information
?
-
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification
-
-
?
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
specificity of phospholipid binding by 15-LOX-2, overview
-
-
?
additional information
?
-
the enzymatic peroxidation reaction consists of four consecutive steps: At first a hydrogen atom is stereoselectively abstracted from one of the bisallylic methylene-groups forming an enzyme-bound radical. Secondly one of the two associated cis-double bonds is rearranged and forms a conjugated cis-trans-diene. Consecutively a peroxy radical is produced by inserting molecular oxygen. Finally the radical is reduced by antarafacial re-inserting of a hydrogen atom. The resulting product of this peroxidation reaction depends on the respective fatty acid, which is used as a substrate
-
-
?
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
the enzyme also converts linoleate to (9Z,11E,13S)-13-hydroperoxy-11,13-octadecadienoate
-
-
?
additional information
?
-
-
the enzyme also converts linoleate to (9Z,11E,13S)-13-hydroperoxy-11,13-octadecadienoate
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
-
a bifunctional enzyme exhibiting 12-LO and 15-LO activity, the enzyme is also able to catalyze stereoselective oxidation of linoleic acid at position 13 over 9 to preferentially form 13(S)-hydroperoxyoctadienoic acid, which enhances MCP-1 expression, overview
-
-
?
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification. Intraenzyme oxygen movement
-
-
?
additional information
?
-
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification. Intraenzyme oxygen movement
-
-
?
additional information
?
-
the enzymatic peroxidation reaction consists of four consecutive steps: At first a hydrogen atom is stereoselectively abstracted from one of the bisallylic methylene-groups forming an enzyme-bound radical. Secondly one of the two associated cis-double bonds is rearranged and forms a conjugated cis-trans-diene. Consecutively a peroxy radical is produced by inserting molecular oxygen. Finally the radical is reduced by antarafacial re-inserting of a hydrogen atom. The resulting product of this peroxidation reaction depends on the respective fatty acid, which is used as a substrate
-
-
?
additional information
?
-
-
a bifunctional enzyme exhibiting 12-LO and 15-LO activity, the enzyme is also able to catalyze stereoselective oxidation of linoleic acid at position 13 over 9 to preferentially form 13(S)-hydroperoxyoctadienoic acid, which enhances MCP-1 expression, overview
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 54% 12-hydroperoxyicosatetraenoate and 46% 15-hydroperoxyicosatetraenoate with 76% overall activity compared to the human enzyme activity
-
-
?
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
the enzyme also converts linoleate to (9Z,11E,13S)-13-hydroperoxy-11,13-octadecadienoate, alpha-linolenate to (9Z,11E,13S,15Z)-13-hydroperoxy-9,11,15-octadecatrienoate and gamma-linolenate to (6Z,9Z,11E,13S)-13-hydroperoxy-6,9,11-octadecatrienoate
-
-
?
additional information
?
-
-
15-lipoxygenase is capable of disrupting the pH gradient maintained by mitochondria in living cells without additional factors specific for red blood cell development. Ectopic expression of 15-lipoxygenase leads to the collaps of the mitochondrial pH gradient in nonerythroid cells
-
-
?
additional information
?
-
-
activation of the enzyme at the protein and product levels and increased sensitivity to constriction of pulmonary arteries by the product 15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid may contribute to pulmonary hypoxic vasoconstriction in neonatal rabbits
-
-
?
additional information
?
-
-
the enzyme may be involved in the development of atherosclerosis
-
-
?
additional information
?
-
-
stereo-selectivity in LOX-catalyzed oxygenation of lysophospholipids, overview
-
-
?
additional information
?
-
-
the bifunctional enzyme also forms (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate, the product of 12-LO activity, EC 1.13.11.31, in a ratio of 9:1 15(S)-HPETE to 12(S)HPETE
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. The wild-type animal produces 3% 12-hydroperoxyicosatetraenoate and 97% 15-hydroperoxyicosatetraenoate
-
-
?
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Molecular docking studies of a phospholipid molecule at the active site of rabbit ALOX15. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification. Intraenzyme oxygen movement
-
-
?
additional information
?
-
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Molecular docking studies of a phospholipid molecule at the active site of rabbit ALOX15. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification. Intraenzyme oxygen movement
-
-
?
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
H2QBX9
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 20% 12-hydroperoxyicosatetraenoate and 80% 15-hydroperoxyicosatetraenoate with 135% overall activity compared to the human enzyme activity
-
-
?
additional information
?
-
H2QBX9
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 78% 12-hydroperoxyicosatetraenoate and 22% 15-hydroperoxyicosatetraenoate with 37% overall activity compared to the human enzyme activity
-
-
?
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 14% 12-hydroperoxyicosatetraenoate and 86% 15-hydroperoxyicosatetraenoate
-
-
?
additional information
?
-
prediction of reaction specificity of mammalian ALOX15 orthologues, and reaction specificity of ALOX15 orthologues during late primate evolution
-
-
?
additional information
?
-
-
production of antiinflammatory lipid mediators by the enzyme may be a general strategy by which pathogens regulate the host-pathogen relationship
-
-
?
additional information
?
-
enzyme LoxA is capable of efficiently catalyzing the peroxidation of a broad range of free fatty acid substrates, e.g. arachidonate and linoleate with high positional specificity, indicating a 15-LOX, its mechanism includes hydrogen atom abstraction. LoxA also does not react with 5- or 15-15-hydroperoxyicosatetraenoates, or phosphoester fatty acids
-
-
?
additional information
?
-
-
enzyme LoxA is capable of efficiently catalyzing the peroxidation of a broad range of free fatty acid substrates, e.g. arachidonate and linoleate with high positional specificity, indicating a 15-LOX, its mechanism includes hydrogen atom abstraction. LoxA also does not react with 5- or 15-15-hydroperoxyicosatetraenoates, or phosphoester fatty acids
-
-
?
additional information
?
-
-
trans-10,cis-12-conjugated linoleic acid is not a substrate for 15-LOX-1
-
-
?
additional information
?
-
in the brain, the principal 12/15-LOX metabolites of arachidonate are (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate, cf. EC 1.13.11.31, and (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
?
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
enzyme substrate specificity, overview. The ALOX15 enzyme activity is not restricted to free polyenoic fatty acids since phospholipids and even biomembranes and lipoproteins are suitable ALOX15 substrates. The ALOX15 orthologue is capable of converting hydroperoxy fatty acids to epoxy leukotrienes. Product specificity with polyenoic acids and with complex substrates, and alteration of product specificity by substrate modification. Intraenzyme oxygen movement
-
-
?
additional information
?
-
in the brain, the principal 12/15-LOX metabolites of arachidonate are (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate, cf. EC 1.13.11.31, and (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
?
additional information
?
-
-
12/15-LO can catalyse the formation of EXC4
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
-
-
-
-
?
additional information
?
-
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
-
-
(5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate slightly increases expression of monocyte chemoattractant protein MCP-1 in macrophages, also but more potent by 12(S)-hydroxyeicosatetranoic acid, overview
-
?
2 arachidonate + 2 O2 + H+
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate + (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate + H2O
-
-
(5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate slightly increases expression of monocyte chemoattractant protein MCP-1 in macrophages, also but more potent by 12(S)-hydroxyeicosatetranoic acid, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
further metabolized to (5Z,8Z,11Z,13E)-(15S)-15-hydroxyeicosa-5,8,11,13-tetraenoate, 15-HETE, has no effect on the spontaneous and lipopolysaccharide-stimulated growth of leukemic blasts
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
the bifunctional enzyme also forms (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate, the product of 12-LO activity, EC 1.13.11.31, in a ratio of 9:1 15(S)-HPETE to 12(S)-HPETE, further reduced to the correspondent (S)-hydroxy fatty acids, in eosinophils, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells, it could be a suppressor of prostate cancer development, which functions by restricting cell cycle progression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
catalyzes enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is implicated in inflammatory disorders, 15-lipoxygenase is induced in atherosclerosis and can oxidize low-density lipoprotein to its atherogenic form
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
alternative splicing of 15S-lipoxygenase provides a further level of regulation of fatty acid metabolism
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
12/15LO protein levels and activity are increased in pathologically affected regions of Alzheimers disease brains, enzyme inhibition causes a decrease in amyloid-beta protein, 12/15LO influences amyloid-beta protein precursor protein metabolism, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
15-lipoxygenase type-1 is a prooxidant enzyme, which is expressed in asthmatic lungs leading to formation of pro- and anti-inflammatory mediators, overview
the product is further metabolized to 15(S)-hydroxyeicosatetranoic acid and 15-ketoeicosatetraenoic acid, the latter is the main product, pathway and mechanism, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
15-LOX2 in NHP cells is positively regulated by Sp1 and negatively regulated by Sp3, but 15-LOX2 expression in NHP cells is not directly regulated by androgen/androgen receptor, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
arachidonic acid is metabolized by the 15-lipoxygenase-1 pathway to the vasodilatory eicosanoids hydroxyepoxyeicosatrienoic acid and trihydroxyeicosatrienoic acid
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
arachidonic acid metabolization by lipoxygenases, overview
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is involved in acetylsalicylic acid-triggered production of 15(S)-hydroxyeicosatetranoic acid, 15(S)-HETE, in sensitive asthmatic patients, acetylsalicylate-tolerant asthma patients show reduced 15-LO activity
is metabolized to 15(S)-hydroxyeicosatetranoic, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme modifies high density lipoprotein 3, the major and most antiatherogenic HDL subfraction, and impairs anti-inflammatory activity of the lipoprotein, which, after modification, fails to inhibit TNFalpha-mediated mRNA and protein induction of adhesion molecules and monocyte chemoattractant protein-1, MCP-1, in endothelial cells, overview
is metabolized to 15(S)-hydroxyeicosatetranoic, i.e. 15(S)-HETE
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
-
is further metabolized by hydroperoxide isomerase to the acid-sensitive metabolite 15(S)-hydroxy-11,12-epoxyeicosatrienoic acid, which is hydrolyzed to 11,12,15-trihydroxyeicosatrienoic acid, by a soluble epoxid hydrolase, causing endothelium-dependent smooth muscle hyperpolarization and relaxations, mass spectrometrical metabolite analysis and pathway, overview
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
catalyzes enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
first step in biotransformation of arachidonic acid to the 15-series of leukotrienes, reaction is involved in inactivation of slow-reacting substrances of anaphylaxis
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
the enzyme is regulated pretranslational, translational and posttranslational
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
-
induction of experimental anemia leads to a systemic up-regulation of 12/15-lipoxygenases expression
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
best substrate
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
H2QBX9
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
-
?
additional information
?
-
-
the enzyme may be involved in the development of atherosclerosis
-
-
?
additional information
?
-
-
15-LOX2 and 15-LOX2sv-b suppress prostate tumor development, and the tumor-suppressive functions apparently do not necessarily depend on arachidonic acid-metabolizing activity and nuclear localization
-
-
?
additional information
?
-
15-LOX2 is a functional tumor suppressor that regulates prostate epithelial cell differentiation, senescence, and growth size, overview
-
-
?
additional information
?
-
-
15-LOX2 is a functional tumor suppressor that regulates prostate epithelial cell differentiation, senescence, and growth size, overview
-
-
?
additional information
?
-
-
eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in eosinophils and mast cells, metabolism of 14,15-leukotrienes in eosinophils, overview
-
-
?
additional information
?
-
-
15LO1 interacts with PEBP1 (phosphatidylethanolamine-binding protein)
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type subject produces 21% 12-hydroperoxyicosatetraenoate and 79% 15-hydroperoxyicosatetraenoate
-
-
?
additional information
?
-
15-LOX is a non-heme iron-containing dioxygenase that oxygenates polyunsaturated fatty acids (PUFA) containing cis,cis-1,4-pentadiene moieties
-
-
?
additional information
?
-
human 15-LOX type 1 (ALOX15) is a predominantly 15-lipoxygenating enzyme, which produces only little amounts of (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate (ratio of 9:1)
-
-
?
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation. Intraenzyme oxygen movement
-
-
?
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation. Intraenzyme oxygen movement
-
-
?
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 54% 12-hydroperoxyicosatetraenoate and 46% 15-hydroperoxyicosatetraenoate with 76% overall activity compared to the human enzyme activity
-
-
?
additional information
?
-
-
15-lipoxygenase is capable of disrupting the pH gradient maintained by mitochondria in living cells without additional factors specific for red blood cell development. Ectopic expression of 15-lipoxygenase leads to the collaps of the mitochondrial pH gradient in nonerythroid cells
-
-
?
additional information
?
-
-
activation of the enzyme at the protein and product levels and increased sensitivity to constriction of pulmonary arteries by the product 15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid may contribute to pulmonary hypoxic vasoconstriction in neonatal rabbits
-
-
?
additional information
?
-
-
the enzyme may be involved in the development of atherosclerosis
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. The wild-type animal produces 3% 12-hydroperoxyicosatetraenoate and 97% 15-hydroperoxyicosatetraenoate
-
-
?
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
H2QBX9
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 20% 12-hydroperoxyicosatetraenoate and 80% 15-hydroperoxyicosatetraenoate with 135% overall activity compared to the human enzyme activity
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 78% 12-hydroperoxyicosatetraenoate and 22% 15-hydroperoxyicosatetraenoate with 37% overall activity compared to the human enzyme activity
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview
-
-
?
additional information
?
-
15-lipoxygenating ALOX15 orthologs exhibit significantly higher lipoxin-synthesizing capacities than 12-lipoxygenating. Product pattern of primate ALOX15 orthologues, overview. The wild-type animal produces 14% 12-hydroperoxyicosatetraenoate and 86% 15-hydroperoxyicosatetraenoate
-
-
?
additional information
?
-
-
production of antiinflammatory lipid mediators by the enzyme may be a general strategy by which pathogens regulate the host-pathogen relationship
-
-
?
additional information
?
-
in the brain, the principal 12/15-LOX metabolites of arachidonate are (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate, cf. EC 1.13.11.31, and (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
?
additional information
?
-
the major reaction products are identified as(8S,15S,5Z,9E,11Z,13E)-8,15-dihydroperoxy-5,9,11,13-eicosatetraenoic acid (8S,15S-DiHpETE) and (5S,15S,6E,8Z,11Z,13E)-5,15-dihydroperoxy-6,8,11,13-eicosatetraenoic acid (5S,15S-DiHPETE) and the stereochemistry of the reaction is compatible with an inverse substrate orientation
-
-
?
additional information
?
-
in the brain, the principal 12/15-LOX metabolites of arachidonate are (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate, cf. EC 1.13.11.31, and (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-5,7-O-diacetyl-3',4',5'-O-triacetylepigallocatechin-3-O-(3'',4'',5''-O-triacetyl)gallate
-
IC50: 0.061 mM
(-)-5,7-O-dibutyryl-3',4',5'-O-tributyrylepigallocatechin-3-O-(3'',4'',5''-O-tributyryl) gallate
-
IC50: 0.033 mM
(-)-5,7-O-dimethyl-3',4',5'-O-trimethylepigallocatechin-3-O-(3'',4'',5''-O-trimethyl) gallate
-
IC50: 0.03 mM
(-)-5,7-O-dipropionyl-3',4',5'-O-tripropionylepigallocatechin-3-O-(3'',4'',5''-O-tripropionyl) gallate
-
IC50: 0.031 mM
(-)-epigallocatechin-3-gallate
-
IC50: 0.1 mM
(-)-jaspic acid
-
IC50: 0.0014 mM
(Z)-9-octadecenyl sulfate
-
allosteric inhibition
1,2,3-triphenylindolizine-7-carbonitrile
-
IC50: 0.028 mM
1-(((2,4,6-trimethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.017 mM
1-(((2,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.027 mM
1-(((2,5-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.015 mM
1-(((2-methyl)ethylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.042 mM
1-(((2-methyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.022 mM
1-(((2-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.021 mM
1-(((3,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.019 mM
1-(((3-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.023 mM
1-(((4-(2-methylethyl)phenl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.016 mM
1-(((4-chlorophenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.022 mM
1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.2 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.22 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methoxyphenyl)-7-indolizinecarbonitrile
-
IC50: 0.024 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
-
IC50: 0.2 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-dibutyl-7-indolizinecarbonitrile
-
IC50: 0.03 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diethyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarboxaldehyde
-
IC50: 0.02 mM
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinylethanone
-
IC50: 0.023 mM
1-(((4-methysulfonyllphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.024 mM
1-(((4-trifluoromethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.023 mM
1-((4-methylphenyl)sulfonyl)2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-((butylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.028 mM
1-((methylsulfonyl)oxy)-2,3-diphenyl-7-indolizine-carbonitrile
-
IC50: 0.022 mM
1-((N,N-dimethylaminosulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.025 mM
1-((phenylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.024 mM
1-(1,3-dibenzyloxy-2-propyloxy)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-(1-Hydroxy-1-phenyl-ethyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.017 mM
1-(1-hydroxyethyl)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.026 mM
1-(2-furyl)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.024 mM
1-(2-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.02 mM
1-(2-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.029 mM
1-(3-chlorobenzoyl)-N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
1-(3-chlorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-(3-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.02 mM
1-(4-chlorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-(4-fluorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.035 mM
1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
1-(4-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.032 mM
1-(4-methylphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.037 mM
1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one
-
1-(Cyclohexyl-hydroxy-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.023 mM
1-(Hydroxy-p-tolyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.022 mM
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
1-(hydroxymethyl)-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.026 mM
1-(hydroxymethyl)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.034 mM
1-(Methoxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.021 mM
1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile
1-acetyl-2,3-diphenylindolizine-7-carbonitrile
1-acetyl-N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
1-benzoyl-2,3-diphenylindolizine-7-carbonitrile
1-benzyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.027 mM
1-benzyl-N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile
1-formyl-2,3-diphenylindolizine-7-carbonitrile
1-methoxy-2,3-diphenylindolizine-7-carbonitrile
1-methyl-2,3-diphenylindolizine-7-carbonitrile
1-phenyl-2-([[4-(trifluoromethyl)phenyl]methyl]sulfanyl)-1H-imidazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
-
1-phenylmethoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.031 mM
1-[(2H-1,3-benzodioxol-5-yl)carbamothioyl]-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
1-[(4-Chloro-phenyl)-hydroxy-methyl]-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.023 mM
1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
-
1-[4-[4-([[5-(3-chlorophenyl)furan-2-yl]methyl]amino)phenyl]piperazin-1-yl]ethan-1-one
-
1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
-
1-[Hydroxy-(4-methoxy-phenyl)-methyl]-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.017 mM
11-hydroxytephrosin
-
IC50: 0.071 mM
11-thialinoleic acid
-
is a noncompetitive inhibitor of 15-lipoxygenase-1 with respect to arachidonate or linoleic acid as substrates. Presence of inhibitor does not alter the product distribution for 15-lipoxygenase-1. It does not change the regioselectivity of 15-lipoxygenase-1
12alpha-hydroxydeguelin
-
IC50: 0.018 mM
12alpha-hydroxyrotenone
-
IC50: 0.102 mM
13S-hydroperoxy-9E,11E-octadecydienoic acid
-
rapidly inactivates
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
2,3,4,5-tetrabromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
-
IC50: 0.00079 mM
2,3,5-tribromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
-
IC50: 0.0022 mM
2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.033 mM
2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile
-
IC50: 0.03 mM
2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
-
IC50: 0.027 mM
2,3-Dihydroxybenzoic acid
-
47.7% inhibition at 0.015 mM, active site binding structure
2,3-diphenyl-1-(2-thienyl)indolizine-7-carbonitrile
-
IC50: 0.02 mM
2,3-diphenyl-1-(3-thienyl)indolizine-7-carbonitrile
-
IC50: 0.019 mM
2,3-diphenyl-1-indolizinol tosylate
-
IC50: 0.025 mM
2,3-diphenylindolizine-7-carbonitrile
2,4-dibromo-6-(2,4-dibromo-6-methoxyphenoxy)phenol
-
IC50: 0.01 mM
2,4-Dibromophenol
-
IC50: 0.034 mM
2,4-dihydroxybenzoic acid
-
49.9% inhibition at 0.015 mM, active site binding structure
2,5-dihydroxybenzoic acid
-
21.2% inhibition at 0.015 mM, active site binding structure
2,6-dibromo-4-[1-(3-bromo-4-hydroxyphenyl)-1-methylethyl]phenol
-
IC50: 0.005 mM
2-(1H-indol-3-yl)-N-[(4-pentylphenyl)sulfonyl]acetamide
-
-
2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole
2-(4-ethylpiperazin-1-yl)4-methylpyrimido[4,5-b][1,4]benzothiazine
-
-
2-(4-ethylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(4-methylpiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(piperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-(pyrrolidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
2-([4-[(4-fluorobenzyl)oxy]butyl]sulfanyl)-5-(naphthalen-1-yl)-1,3,4-oxadiazole
-
-
2-alkyl benzopyran-4-ones
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
2-alkyl-6-hydroxy-4-H-benzopyran-4-one
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
2-hydroxybenzoic acid
-
46.0% inhibition at 0.015 mM, active site binding structure
2-phenyl-3-[3-(pyridin-3-yl)-4,5-dihydro-1H-pyrazol-5-yl]-1H-indole
molecular docking, compound is stabilized in the catalytic pocket of enzyme by pi-cation interaction with the catalytic Fe+ and formation of one hydrogen bond with Ile 676 amino acid
-
2-[2-(1H-indol-3-yl)ethyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[2-(2-bromo-1H-indol-3-yl)ethyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[3-(1H-indol-3-yl)propyl]-1H-isoindole-1,3(2H)-dione
-
-
2-[4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy]-N,N-dimethylethan-1-amine
-
2-[[(4-bromophenyl)methyl]sulfanyl]-1-phenyl-1H-imidazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
-
2-[[(4-ethylphenyl)methyl]sulfanyl]-1-phenyl-1H-imidazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
-
3'-chloro-7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
3'-naphthalen-2-yl-1'-phenyl-5-p-tolyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid amide
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
3'-naphthalen-2-yl-5,1'-diphenyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid amide
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
3'-naphthalen-2-yl-5,1'-diphenyl-3,4-dihydro-2H,1'H-[3,4']bipyrazole
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
3,4,5-Trihydroxybenzoic acid
-
60.5% inhibition at 0.015 mM, active site binding structure
3,4,6,8-tetrabromooxanthren-1-ol
-
IC50: 0.0009 mM
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)phenol
-
IC50: 0.011 mM
3,4-dihydroxybenzoic acid
-
51.6% inhibition at 0.015 mM, active site binding structure; 73.3% inhibition at 0.015 mM, active site binding structure
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
3,5-Dihydroxybenzoic acid
-
58.1% inhibition at 0.015 mM, active site binding structure
3,6,8-tribromooxanthren-1-ol
-
IC50: 0.0008 mM
3-(2-[[(4-pentylphenyl)sulfonyl]amino]ethyl)-1H-indole-6-carboxylic acid
-
-
3-(4-bromophenyl)-6-(4-chlorophenyl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-bromophenyl)-6-(4-chlorophenyl)-N-cyclohexylimidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-bromophenyl)-N-cyclohexyl-6-(2-nitrophenyl)imidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-methoxyphenyl)-5-(3-naphthalen-2-yl-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydro-1,2-oxazole
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
3-(4-methoxyphenyl)-6-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
protective activity of compound 5i against H2O2-induced cell death in differentiated PC12 cells
3-hydroxy-H-benzopyran-4-one derivatives
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
3-Hydroxybenzoic acid
-
47.6% inhibition at 0.015 mM, active site binding structure
3-[1-[(4-pentylphenyl)sulfonyl]pyrrolidin-3-yl]-1H-indole
-
-
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
3-[[(4-methylphenyl)methyl]sulfanyl]-1-phenyl-1H-1,2,4-triazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
-
4',6,7-trihydroxyisoflavan
-
-
4',6,7-trihydroxyisoflavanone
-
weak inhibition of isozyme 15-hLO-2
4',6,7-trihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
4'-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00053 mM in the presence of arachidonate, IC50: 0.0002 mM in the presence of linoleic acid
4'-chloro-7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
4'-ethyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00026 mM in the presence of arachidonate, IC50: 0.00047 mM in the presence of linoleic acid
4'-tert-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.00027 mM in the presence of arachidonate, IC50: 0.00023 mM in the presence of linoleic acid
4,4'-(2,3-dimethylbutane-1,4-diyl)di(benzene-1,2-diol)
-
4,4'-propane-2,2-diylbis(2,6-dibromophenol)
-
IC50: 0.004 mM
4,5-bis(4-chlorophenyl)-1H-imidazole-2-thiol
-
-
4,5-bis(4-fluorophenyl)-1H-imidazole-2-thiol
-
-
4,5-bis(4-methoxyphenyl)-1H-imidazole-2-thiol
-
-
4,5-dichloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
4,5-diphenyl-1H-imidazole-2-thiol
-
-
4,7,10,13-eicosatetraenoic acid
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)butyl)-4-fluorobenzoate
-
-
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)methyl)-benzyl-4-fluorobenzoate
-
-
4-(2-benzoylhydrazinyl)benzene-1-sulfonamide
10% inhibition
4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
-
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(4-chlorophenyl)-5-phenyl-1H-imidazole-2-thiol
-
-
4-(4-methoxyphenyl)-5-phenyl-1H-imidazole-2-thiol
-
-
4-(5-(1H-indol-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(3-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(3-hydroxynaphthalen-2-yl)-1,3,4-oxadiazol-2-ylthio)-but-2-ynyl-4-fluorobenzoate
-
low solubility
4-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(furan-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylamino)but-2-ynyl-thiophene-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-yn-1-ol
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-1H-indole-4-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-benzofuran-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-thiadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
low solubility
4-(5-(quinolin-5-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(thiophen-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-phenyl-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-(3-hydroxypropyl)benzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-(4-methoxyphenyl)benzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-butylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-cyclohexylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-phenylbenzamide
-
-
4-([2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]sulfamoyl)-N-[3-(dimethylamino)propyl]benzamide
-
-
4-([2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]sulfamoyl)benzoic acid
-
-
4-allyl-2-methoxyphenyl 1-adamantanecarboxylate
4-allyl-2-methoxyphenyl 1-cyclohexanecarboxylate
4-allyl-2-methoxyphenyl 2-chlorobenzoate
4-allyl-2-methoxyphenyl 2-fluorobenzoate
4-allyl-2-methoxyphenyl 2-methylbenzoate
4-allyl-2-methoxyphenyl 2-pyridinecarboxylate
4-allyl-2-methoxyphenyl 3-chlorobenzoate
4-allyl-2-methoxyphenyl 3-fluorobenzoate
4-allyl-2-methoxyphenyl 3-methoxybenzoate
4-allyl-2-methoxyphenyl 3-methylbenzoate
4-allyl-2-methoxyphenyl 4-chlorobenzoate
4-allyl-2-methoxyphenyl 4-fluorobenzoate
4-allyl-2-methoxyphenyl 4-methoxybenzoate
4-allyl-2-methoxyphenyl 4-methylbenzoate
4-allyl-2-methoxyphenyl benzoate
4-allyl-2-methoxyphenyl isonicotinate
4-allyl-2-methoxyphenyl nicotinate
4-amino-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-bromo-5-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-bromo-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-bromo-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
-
-
4-butyl-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-butyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
-
IC50: 0.00307 mM in the presence of arachidonate, IC50: 0.004 mM in the presence of linoleic acid
4-butyl-N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]benzenesulfonamide
-
-
4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-chloro-N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide
-
4-chloro-N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
4-chlorophenyl 3-[(2-chlorophenyl)carbamoyl]-1H-pyrazole-1-carboxylate
-
4-ethyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
-
IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid
4-hydroxy-3-methoxybenzoic acid
-
45.4% inhibition at 0.015 mM, active site binding structure
4-hydroxybenzoic acid
-
47.0% inhibition at 0.015 mM, active site binding structure
4-methyl-2-(4-ethylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(4-hydroxypiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine
-
-
4-methyl-2-(4-methylpiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(4-phenylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(piperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-methyl-2-(pyrrolidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
-
-
4-nitrocatechol
-
IC50: 0.0046 mM
4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide
-
-
4-pentyl-N-(2-[2-[4-(trifluoromethyl)phenyl]-1H-indol-3-yl]ethyl)benzenesulfonamide
-
-
4-pentyl-N-[2-(2-phenyl-1H-indol-3-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(2-quinolin-3-yl-1H-indol-3-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyrazin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-3-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-[5-(1H-pyrrol-2-yl)-1H-indol-3-yl]ethyl]benzenesulfonamide
-
-
4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide
-
-
4-[(E)-benzoyldiazenyl]benzene-1-sulfonamide
-
4-[(E)-benzoyldiazenyl]benzonitrile
80% inhibition, competitive
4-[4-(dimethylamino)phenyl]-5-(4-methoxyphenyl)-1H-imidazole-2-thiol
-
-
4-[4-(methylsulfanyl)phenyl]-5-phenyl-1H-imidazole-2-thiol
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1H-imidazole-4-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2,4-difluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluoropyridine-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-methoxybenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trichlorothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trifluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4-difluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chloro-1-benzothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chlorothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-fluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(difluoromethoxy)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(methylsulfonyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(triazan-2-yl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethoxy)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-bromobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-chloro-3-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-[(trifluoromethyl)sulfanyl]benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclobutanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopentanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopropanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl furan-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl naphthalene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl thiophene-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]butyl 4-fluorobenzoate
-
-
4-[[5-(naphthalen-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-fluorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-chlorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-fluorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-methoxybenzoate
-
-
5,8,11,14,17-eicosapentaenoic acid
5,8,11,14-eicosatetraenoic acid
5,8,11,14-Eicosatetraynoic acid
5-(3,4-dichlorophenyl)-3'-naphthalen-2-yl-1'-phenyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
5-(3,4-dichlorophenyl)-3'-naphthalen-2-yl-2,1'-diphenyl-3,4-dihydro-2H,1'H-[3,4']-bipyrazole
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
5-(3-naphthalen-2-yl-1-phenyl-1H-pyrazol-4-yl)-3-p-tolyl-4,5-dihydro-1,2-oxazole
-
compound shows radical scavenging activity in comparison with ascorbic acid and 15-LOX inhibition potency
-
5-(4-chlorophenyl)-4-(4-methoxyphenyl)-1H-imidazole-2-thiol
-
-
5-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-(methylsulfanyl)-1H-imidazole
-
-
5-(4-chlorophenyl)-4-[4-(dimethylamino)phenyl]-1H-imidazole-2-thiol
-
-
5-(4-chlorophenyl)-4-[4-(methylsulfanyl)phenyl]-1H-imidazole-2-thiol
-
-
5-(4-fluorophenyl)-4-(4-methoxyphenyl)-1H-imidazole-2-thiol
-
-
5-(4-fluorophenyl)-4-[4-(methylsulfanyl)phenyl]-1H-imidazole-2-thiol
-
-
5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine
5-(methylamino)-2-(naphthalen-1-yl)-4,5-dihydro-1,3-oxazole-4-carbonitrile
-
-
5-amino-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
5-butyl-N3-(2-chloro-4-fluorophenyl)-N1-hexyl-1H-pyrazole-1,3-dicarboxamide
-
5-chloro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
5-chloro-N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
-
5-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
5-ethoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
-
IC50: 0.028 mM
5-fluoro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
5-tert-butyl-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
6,11-dihydro[1]benzothiopyrano[4,3-b]indole
-
PD146176
6,6a,11,11a-tetrahydro[1]benzothiopyrano[4,3-b]indole
-
-
6,7-dihydroxy-2-t-butylbenzopyran-4-one
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxy-3',4'-methylenedioxyisoflavan
-
-
6,7-dihydroxy-3'-methylisoflavan
-
-
6,7-dihydroxy-3'-methylisoflavanone
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxy-4'-methoxyisoflavan
-
-
6,7-dihydroxy-4'-methoxyisoflavanone
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxyisoflavones
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
6,7-dimethoxy-2,3-dihydrochromone
-
IC50: 0.137 mM
6,7-diphenylpyrrolo[1,2-a]pyrimidin-8-ol tosylate
-
IC50: 0.015 mM
6,7-diphenylpyrrolo[1,2-b]pyridazin-5-yl trifluoromethanesulfonate
-
IC50: 0.043 mM
6,7-diphenylpyrrolo[1,2-c]pyrimidin-5-ol tosylate
-
IC50: 0.022 mM
6-(2-bromophenyl)-N-cyclohexyl-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
6-(2-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
6-(4-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
6-chloro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-chloro-2-(4,5-dichloro-1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-chloro-2-(5-chloro-1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-fluoro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-hydroxy-2-pentyl-4H-benzopyran-4-one
-
weak inhibition of isozyme 15-hLO-2
6-oxo-6alpha,12alpha-dehydrodeguelin
-
-
6-[4-([1,1'-biphenyl]-2-yl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
-
6-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]-1-phenylhexan-1-one
-
low solubility
6alpha,12alpha-12alpha-hydroxyelliptone
-
IC50: 0.062 mM
6alpha,12alpha-dehydrodeguelin
-
IC50: 0.071 mM
7,10,13-eicosatrienoic acid
7,8-dihydroxy-3',4'-dimethoxyisoflavan
-
-
7,8-dihydroxy-3'-methylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxy-3'-trifluoromethylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxy-4'-methoxyisoflavan
-
-
7,8-dihydroxy-4'-methylisoflavan
-
-
7,8-dihydroxy-4'-methylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
7-(1,1-dimethylethyl)-2,3-diphenyl-1-indolizinol tosylate
-
IC50: 0.022 mM
7-cyano-2,3-diphenylindolizin-1-yl 2-methoxybenzoate
-
IC50: 0.03 mM
7-cyano-2,3-diphenylindolizin-1-yl 3-methoxybenzoate
-
IC50: 0.028 mM
7-cyano-2,3-diphenylindolizin-1-yl 4-methoxybenzoate
-
IC50: 0.028 mM
7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate
7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
-
7-hydroxy-H-benzopyran-4-one derivatives
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
8,11,14-eicosatrienoic acid
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
-
AAAKKAAK
-
64.2% inhibition at 0.25 mM
adamantyl caffeate
IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.074 mM
-
alpha-mangostin
-
NSC30552, a natural product, caspase-3 pathway inhibitor, performs selective inhibition of 12-LO
arachidonic acid
-
autoinactivates 15-hLO-1 to a much greater extent than linoleic acid at high substrate concentrations. No autoinactivation at low substrate concentrations
barbigerone
-
IC50: 0.063 mM
benzoic acid
-
48.4% inhibition at 0.015 mM, active site binding structure
bestatin
-
IC50: 0.027 mM
bestatin 7
-
IC50: 0.027 mM
beta-casein
-
11.7% inhibition at 0.025 mM
-
bornyl vanillate
IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.401 mM
-
cinnamyl 3,4-dihydroxy-cyanocinnamate
-
CDC
cinnamyl-3,4-dihydroxy-a-cyanocinnamate
-
-
cinnamyl-3,4-dihydroxy-cyanocinnamate
-
conjugated linoleic acids
-
conjugated linoleic acids may function as inhibitors of 15-LO-1 activity in macrophages/in vivo, overview
-
dansyl tryptamine
-
IC50: 0.00373 mM
eicosatetraynoic acid
-
-
epicatechin
-
IC50: 0.06 mM
ethyl 6-([3-[(2-chloro-4-fluorophenyl)carbamoyl]-1H-pyrazole-1-carbonyl]amino)hexanoate
-
ethyl 6-chloro-3-[(3S)-3-hydroxy-7-methyloctanoyl]-2,3-dihydro-1H-indole-2-carboxylate
-
-
fenchyl caffeate
IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.089 mM
-
GATA-6
-
inhibits non-steroidal anti-inflammatory drugs-induced transcription of 15-LOX-1 in colorectal cancer cells
-
genistin
-
IC50: above 0.167 mM
glucocorticoid
-
inhibits induction in monocytes
-
glucosyringic acid
-
IC50: above 0.167 mM
hesperetin
-
IC50: 0.09 mM
interferon-gamma
-
inhibits induction in monocytes
-
iodoacetamide
-
1.0 mM, 30% inhibition
IRKEIKKN
-
33.9% inhibition at 0.25 mM
isotachioside
-
IC50: above 0.167 mM
jaspaquinol
-
IC50: 0.0003 mM
L-carnosine
-
3.6% inhibition at 0.25 mM
methyl 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate
-
methyl 3-(2-[[(4-pentylphenyl)sulfonyl]amino]ethyl)-1H-indole-6-carboxylate
-
-
michellamine B
-
NSC661755, potent but non-selective inhibitor, a natural anti-viral agent
N'-(4-bromophenyl)benzohydrazide
28% inhibition
N'-(4-cyanophenyl)benzohydrazide
9% inhibition
N'-(4-methoxyphenyl)benzohydrazide
73% inhibition
N'-(4-methylphenyl)benzohydrazide
93% inhibition, competitive
N'-(4-nitrophenyl)benzohydrazide
17% inhibition
N'-phenylbenzohydrazide
33% inhibition
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N,2-dihydroxybenzamide
-
IC50: 0.057 mM
N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
N-(2,5-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-(dimethylsulfamoyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-(phenylacetyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-[3-(trifluoromethyl)benzene-1-sulfonyl]-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
N-(2-chloro-4-fluorophenyl)-4,5-bis(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-fluoro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-iodo-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-methyl-5-(trimethylsilyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-nitro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-phenyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-iodo-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-nitro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide
-
N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chlorophenyl)-N-methyl-1H-pyrazole-3-carboxamide
-
N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol)-2-ylthio)but-2-ynyl-thiophene-2-carboxamide
-
-
N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
N-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazole-3-carboxamide
-
N-(5-chloropyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(5-fluoropyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(7-fluoroquinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(isoquinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-4-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-6-yl)-1H-pyrazole-3-carboxamide
-
N-(tert-butyl)-3-phenyl-6-(p-tolyl)imidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-chlorophenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-methoxyphenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-nitrophenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-benzyl-1H-pyrazole-3-carboxamide
-
N-cyclohexyl-6-(2-fluorophenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-cyclohexyl-6-(4-methoxyphenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-cyclohexyl-6-(4-nitrophenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide
-
-
N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide
-
-
N-phenyl-1H-pyrazole-3-carboxamide
-
N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide
-
-
N-[(5-bromo-8-hydroxy-5,6,7,8-tetrahydroquinolin-7-yl)(thiophen-2-yl)methyl]acetamide
-
N-[2-(1H-indol-3-yl)-1-methylethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(1H-indol-3-yl)ethyl]-2'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00092 mM in the presence of arachidonate, IC50: 0.00046 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-3'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00045 mM in the presence of arachidonate, IC50: 0.00032 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-(1-methylethyl)biphenyl-4-sulfonamide
-
IC50: 0.00028 mM in the presence of arachidonate, IC50: 0.00014 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-(2-methylpropyl)biphenyl-4-sulfonamide
-
IC50: 0.00091 mM in the presence of arachidonate, IC50: 0.00017 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-methoxybiphenyl-4-sulfonamide
-
IC50: 0.0015 mM in the presence of arachidonate, IC50: 0.00109 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4'-methylbiphenyl-4-sulfonamide
-
IC50: 0.00047 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-methylbenzenesulfonamide
-
IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
IC50: 0.00042 mM in the presence of arachidonate, IC50: 0.00102 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-4-propylbenzenesulfonamide
-
IC50: 0.00313 mM in the presence of arachidonate, IC50: 0.0032 mM in the presence of linoleic acid
N-[2-(1H-indol-3-yl)ethyl]-N-methyl-4-pentylbenzenesulfonamide
-
-
N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
-
IC50: 0.0034 mM in the presence of arachidonate, IC50: 0.0042 mM in the presence of linoleic acid
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-dibenzo[b,d]furan-2-yl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-methyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(5-fluoro-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(5-methyl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(7-methyl-1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1-methyl-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-(hydrazinocarbonyl)benzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-bromobenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]ethyl]-4-pyridin-4-ylbenzenesulfonamide
-
-
N-[2-[2-(2,5-dimethoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(2-methyl-1,3-thiazol-4-yl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-chlorophenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-ethoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-1H-indol-3-yl]ethyl]biphenyl-4-sulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methylphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide
-
-
N-[3-(1H-indol-3-yl)propyl]-4-pentylbenzenesulfonamide
-
-
N-[3-(2,5-diphenyl-1H-imidazol-4-yl)propyl]-4-pentylbenzenesulfonamide
-
-
N-[3-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]propyl]-4-pentylbenzenesulfonamide
-
-
N-[3-[2-(1-benzofuran-2-yl)-1H-indol-3-yl]propyl]biphenyl-4-sulfonamide
-
-
N-[4-(1H-indol-3-yl)butyl]-4-pentylbenzenesulfonamide
-
-
N-[4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide
-
N-[4-fluoro-2-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide
-
N1-(2H-1,3-benzodioxol-5-yl)-N-3-(2-chloro-4-fluorophenyl)-1H-pyrazole-1,3-dicarboxamide
-
N1-butyl-N3-(2-chlorophenyl)-N3-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)-N1-hexyl-5-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chloro-4-fluorophenyl)-N1-hexyl-4-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chloro-4-fluorophenyl)-N1-pentyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chlorophenyl)-N1,N1-dimethyl-1H-pyrazole-1,3-dicarboxamide
-
naringenin
-
IC50: 0.25 mM
neodysidenin
-
natural product from marine sponge Dysidea herbacea from Papua New Guinea, extraction and purification, overview, steady-state inhibition kinetics, competitive mode of inhibition, selective for 12-LO
nor-dihydro-guaiaretic acid
-
-
nordihydroguaiaretic acid
NSC172033
-
a synthetic compound from the NCI library
NSC292213
-
a synthetic compound from the NCI library
NSC617570
-
a synthetic compound from the NCI library
NVPGEIVE
-
65.0% inhibition at 0.25 mM
PCMB
-
0.1 mM, 30% inhibition
PD 146 176
-
IC50: 0.00038 mM
PD-146176
-
IC50: 0.00381 mM
phenyl[(E)-phenyldiazenyl]methanone
87% inhibition
PKYPVEPFTE
-
74.6% inhibition at 0.25 mM
propyl gallate
-
96% inhibition at 0.05 mM
RINKKIEK
-
68.1% inhibition at 0.25 mM, a beta-casein-derived octapeptide
RINKKIPK
-
57.7% inhibition at 0.25 mM
sarcolobin
-
IC50: 0.06 mM
SITRINKK
-
65.3% inhibition at 0.25 mM
squalene
-
IC50 is 0.0012 mM
stylosin
IC50 value of cytotoxicity against PC-3 cells, 24 h, is 0.101 mM
-
tachioside
-
IC50: above 0.167 mM
tephrosin
-
IC50: 0.064 mM
tert-butylhydroxyanisol
-
IC50: 0.16 mM
Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester
toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester
vanillic acid 4-O-beta-D-glucoside
-
IC50: 0.161 mM
[(E)-(4-bromophenyl)diazenyl](phenyl)methanone
44% inhibition
[(E)-(4-methoxyphenyl)diazenyl](phenyl)methanone
19% inhibition
[(E)-(4-methylphenyl)diazenyl](phenyl)methanone
44% inhibition
[(E)-(4-nitrophenyl)diazenyl](phenyl)methanone
34% inhibition
1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.02 mM
1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.037mM
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.035 mM
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
-
IC50: 0.048 mM
1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.031 mM
1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.075 mM
1-acetyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.023 mM
1-acetyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.044 mM
1-benzoyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.023 mM
1-benzoyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.043 mM
1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.027 mM
1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile
-
IC50: 0.039 mM
1-formyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.029 mM
1-formyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.061 mM
1-methoxy-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.033 mM
1-methoxy-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.077 mM
1-methyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.027 mM
1-methyl-2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.046 mM
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
-
IC50: 0.007 mM
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
-
IC50: 0.0018 mM
2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.03 mM
2,3-diphenylindolizine-7-carbonitrile
-
IC50: 0.051 mM
2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole
mixed-type inhibitor, performs as potent inhibitor in a HEK-293 cell-based assay and binds in the U-shaped channel of 15-Lox-2
2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole
-
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
-
IC50: 0.009 mM
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
-
IC50: 0.005 mM
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
IC50: 0.05 mM
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
IC50: 0.015 mM
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
-
IC50: 0.059 mM
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
-
IC50: 0.059 mM
4,5-dichloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4,5-dichloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4,7,10,13-eicosatetraenoic acid
-
-
4,7,10,13-eicosatetraenoic acid
-
-
4-allyl-2-methoxyphenyl 1-adamantanecarboxylate
-
-
4-allyl-2-methoxyphenyl 1-adamantanecarboxylate
-
-
4-allyl-2-methoxyphenyl 1-cyclohexanecarboxylate
-
-
4-allyl-2-methoxyphenyl 1-cyclohexanecarboxylate
-
-
4-allyl-2-methoxyphenyl 2-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 2-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 2-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 2-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 2-methylbenzoate
-
-
4-allyl-2-methoxyphenyl 2-methylbenzoate
-
-
4-allyl-2-methoxyphenyl 2-pyridinecarboxylate
-
-
4-allyl-2-methoxyphenyl 2-pyridinecarboxylate
-
-
4-allyl-2-methoxyphenyl 3-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 3-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 3-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 3-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 3-methoxybenzoate
-
-
4-allyl-2-methoxyphenyl 3-methoxybenzoate
-
-
4-allyl-2-methoxyphenyl 3-methylbenzoate
-
-
4-allyl-2-methoxyphenyl 3-methylbenzoate
-
-
4-allyl-2-methoxyphenyl 4-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 4-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 4-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 4-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 4-methoxybenzoate
-
-
4-allyl-2-methoxyphenyl 4-methoxybenzoate
-
-
4-allyl-2-methoxyphenyl 4-methylbenzoate
-
-
4-allyl-2-methoxyphenyl 4-methylbenzoate
-
-
4-allyl-2-methoxyphenyl benzoate
-
-
4-allyl-2-methoxyphenyl benzoate
-
-
4-allyl-2-methoxyphenyl isonicotinate
-
-
4-allyl-2-methoxyphenyl isonicotinate
-
-
4-allyl-2-methoxyphenyl nicotinate
-
-
4-allyl-2-methoxyphenyl nicotinate
-
-
4-Bromophenol
-
IC50: 0.048 mM
4-Bromophenol
-
IC50: 0.055 mM
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate
-
5,8,11,14,17-eicosapentaenoic acid
-
-
5,8,11,14,17-eicosapentaenoic acid
-
-
5,8,11,14-eicosatetraenoic acid
-
-
5,8,11,14-eicosatetraenoic acid
-
-
5,8,11,14-eicosatetraenoic acid
-
IC50: 0.00012 mM
5,8,11,14-Eicosatetraynoic acid
-
-
5,8,11,14-Eicosatetraynoic acid
-
0.0009 mM, 50% inhibition
5,8,11,14-Eicosatetraynoic acid
-
inhibits reaction of linoleic acid
5,8,11,14-Eicosatetraynoic acid
-
-
5,8,11,14-Eicosatetraynoic acid
-
-
5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine
-
IC50: 0.032 mM
5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine
-
IC50: 0.059 mM
5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
-
IC50: 0.029 mM
5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
-
IC50: 0.059 mM
7,10,13-eicosatrienoic acid
-
-
7,10,13-eicosatrienoic acid
-
-
7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate
-
IC50: 0.046 mM
7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate
-
IC50: 0.059 mM
8,11,14-eicosatrienoic acid
-
-
8,11,14-eicosatrienoic acid
-
-
AA-861
-
apigenin
-
IC50: 0.5 mM
apigenin
-
IC50: 0.0034 mM without Triton X-100, IC50: 0.0003 mM in the presence of 0.01% Triton X-100
baicalein
-
IC50: 0.035 mM
baicalein
-
potent inhibitor, IC50: 0.0016 mM without Triton X-100, IC50: 0.038 mM in the presence of 0.01% Triton X-100
baicalein
-
IC50: 0.001 mM
BODIPY-D3825
-
competes with the substrate fatty acid for binding at the active site
BODIPY-D3825
-
competes with the substrate fatty acid for binding at the active site
caffeic acid
-
36.2% inhibition at 0.015 mM
caffeic acid
-
specific inhibition of 15-LO
caffeic acid
-
specific inhibitor of 15-LOX-1
CDC
CAS-No. 132465-11-3
daidzein
-
IC50: 0.25 mM
ebselen
-
i.e. 2-phenyl-1,2-benzisoselenazol-3(2H)-one, irreversible inhibition, IC50: 0.00006 mM
fisetin
-
IC50: 0.0035 mM
fisetin
-
IC50: 0.0018 mM
flavone
-
IC50: 0.7 mM
galangin
-
IC50: 0.2 mM
galangin
-
IC50: 0.045 mM
gallic acid
-
genistein
-
IC50: 1 mM
genistein
-
IC50: 0.018 mM
genistein
-
IC50: above 0.167 mM
linoleic acid
-
autoinactivates 15-hLO-1 to a much greater extent than linoleic acid at high substrate concentrations. No autoinactivation at low substrate concentrations
linoleic acid
-
fully deuterated, the mode of inhibition, in the presence of 13-(S)-hydroxyoctadecadienoic acid, changes from mixed-type inhibition to competitive inhibition
luteolin
-
IC50: 0.003 mM
luteolin
-
IC50: 0.0006 mM
morin
-
IC50: 0.018 mM
myricetin
-
IC50: 0.006 mM
myricetin
-
IC50: 0.018 mM
N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
nordihydroguaiaretic acid
-
IC50: 0.0018 mM
nordihydroguaiaretic acid
-
0.002 mM, 50% inhibition
nordihydroguaiaretic acid
-
-
nordihydroguaiaretic acid
-
IC50: 0.00011 mM
nordihydroguaiaretic acid
-
-
nordihydroguaiaretic acid
-
nordihydroguaiaretic acid
-
nordihydroguaiaretic acid
-
-
nordihydroguaiaretic acid
-
IC50: 0.0005 mM
nordihydroguaiaretic acid
-
-
nordihydroguaiaretic acid
-
IC50: 0.00011 mM
nordihydroguaiaretic acid
-
nordihydroguaiaretic acid
-
0.0001-0.001 mM
nordihydroguaiaretic acid
-
PD146176
-
-
PD146176
-
selective inhibitor of 12/15-LOX, macrophages treated with PD146176 elaborate reduced levels of interleukin-12 in response to Toxoplasma gondii antigen
quercetin
-
IC50: 0.0045 mM
quercetin
-
IC50: 0.004 mM
quercetin
-
IC50: 0.029 mM
siRNA
-
-
-
siRNA
-
knockdown of 15-LOX-2 expression, decreases chemokine ligand CXCL10 secretion from hypoxic macrophages and reduces T cell migration and CD69 expression
-
siRNA
-
cholesterol-tagged siRNAs targeting mouse leukocyte 12/15-LO reduce 12/15-LO expression in the kidney and confer beneficial effects on diabetes-induced changes in glomerular structure and ECM accumulation
-
taxifolin
-
IC50: 1 mM
taxifolin
-
IC50: 0.025 mM
Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester
-
IC50: 0.017 mM
Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester
-
IC50: 0.028 mM
toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester
-
IC50: 0.017mM
toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester
-
IC50: 0.025 mM
additional information
-
docking experiments and qualitative structure-activity relationship, QSAR, data, overview
-
additional information
-
no inhibition by 2,6-dihydroxybenzoic acid
-
additional information
-
quantitative structure activity relationship analysis using crystal structure, PDB ID 1IK3, EC 1.13.11.12, of the enzyme in complex with 13(S)-hydroperoxy-9(Z)-2,11(E)-octadecadienoic acid, docking studies, inhibitor binding structures, overview
-
additional information
-
docking experiments and structure activity relationship, comparative studies, comparison with the crystal structure with PDB entry: 1IK3, EC 1.13.11.12, overview
-
additional information
-
the enzyme undergoes suicidal inactivation, during fatty acid oxygenation
-
additional information
-
IC50 above 0.1 mM: compound 1a, compound 1b, compound 1d, compound 1e, compound 1g
-
additional information
-
development of an assay method for high throughput screening of libraries for platelet-type 12-hLO selective inhibitors, four organo-mercurial compounds with NCI library IDs NSC20410, NSC268879, NSC321237, and NSC321239, are also found to be selectively inhibitory, but not pursued further due to their potentially toxic side effects, overview
-
additional information
-
comparison of structural requirements for flavonoid inhibitory potency and selectivity against platelet 12-hLO, EC 1.13.11.31, and reticulocyte 15-hLO-1 and prostate epithelial 15-hLO-2, overview, catechols are essential for high potency, isoflavones and isoflavanones tend to select against 12-hLO, isoflavans tend to select against isozyme 15-hLO-1, but few flavonoids target isozyme 15-hLO-2, molecular modeling analysis, overview
-
additional information
-
docking studies, inhibitor binding structures, overview
-
additional information
-
synthesis and evaluation of 2,4,5-tri-substituted imidazoles, which show highly potent inhibition of 15-lipoxygenase with excellent selectivity over the lipoxygenases 5-LO, EC 1.13.11.34, and platelet 12-LO, EC 1.13.11.31
-
additional information
-
sulproston, misoprostol, and ONO-AE-248 inhibit acetylsalicylic acid-induced 15(S)-HETE production
-
additional information
-
enzyme inhibition causes a decrease in amyloid-beta protein
-
additional information
15-LOX2 in NHP cells is negatively regulated by Sp3
-
additional information
-
15-LOX2 in NHP cells is negatively regulated by Sp3
-
additional information
-
intraarticular glucocorticoid treatment does not influence the 15-LO-1 enzyme in rheumatoid arthritis tissue
-
additional information
-
physico-chemical state of the substrate and the complex equilibrium between fatty acid monomers, acid soaps and micelles may impact the reaction specificity of LOX-isoforms
-
additional information
-
15-LOX-1 can be inactivated by epigenetic silencing, hypermethylation of the CpG islands of the 15-LOX-1 promoter results in its reduced transcription in cancers, e.g. lymphomas, lung, prostate and cervix cancers. Brominated phenol esters are potent 15-LOX-1 inhibitors
-
additional information
N-substituted pyrazole-3-carboxamides as inhibitors of human 15-lipoxygenase, overview. No inhibition by 7h and 10a
-
additional information
3-substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1, overview. The 1N-substituent is not essential for activity or selectivity. Additional halogen substituents on the pyrazole ring increase activity. Further development leads to triazole-4-carboxanilides and 2-(3-pyrazolyl) benzoxazoles, which are potent and selective 15-LOX-1 inhibitors
-
additional information
synthesis and evaluation of benzoylhydrazides and their diazene derivatives as inhibitors of 15-lipoxygenase, overview
-
additional information
imidazo[2,1-b]thiazole derivatives as inhibitors of 15-lipoxygenase, synthesis and evaluation of series of 3,6-diphenylimidazo[2,1-b]thiazol-5-amine derivatives, docking study, overview
-
additional information
certain oxazole-4-carbonitrile based LOX inhibitors share a high inhibitory potency for human and mouse ALOX15 but hardly inhibit other mammalian LOX-isoforms
-
additional information
-
certain oxazole-4-carbonitrile based LOX inhibitors share a high inhibitory potency for human and mouse ALOX15 but hardly inhibit other mammalian LOX-isoforms
-
additional information
stylosin and some similar synthetic monoterpenoids show inhibitory effects on 15-LOX. A strong positive correlation is observed between 15-LOX inhibition potential and cytotoxicity of the compounds with apoptosis being the predominant mechanism of induced cell death
-
additional information
-
stylosin and some similar synthetic monoterpenoids show inhibitory effects on 15-LOX. A strong positive correlation is observed between 15-LOX inhibition potential and cytotoxicity of the compounds with apoptosis being the predominant mechanism of induced cell death
-
additional information
-
physico-chemical state of the substrate and the complex equilibrium between fatty acid monomers, acid soaps and micelles may impact the reaction specificity of LOX-isoforms
-
additional information
certain oxazole-4-carbonitrile based LOX inhibitors share a high inhibitory potency for human and mouse ALOX15 but hardly inhibit other mammalian LOX-isoforms
-
additional information
-
certain oxazole-4-carbonitrile based LOX inhibitors share a high inhibitory potency for human and mouse ALOX15 but hardly inhibit other mammalian LOX-isoforms
-
additional information
-
inhibitory and LOX binding abilities of diverse RINKKIEK peptide derivatives, overview
-
additional information
-
pH alterations in the near physiological range impact the iron content of LOX and thus the catalytic activity
-
additional information
certain oxazole-4-carbonitrile based LOX inhibitors share a high inhibitory potency for human and mouse ALOX15 but hardly inhibit other mammalian LOX-isoforms
-
additional information
-
certain oxazole-4-carbonitrile based LOX inhibitors share a high inhibitory potency for human and mouse ALOX15 but hardly inhibit other mammalian LOX-isoforms
-
additional information
inhibitor library screening, none selectively targets LoxA over the human LOX isozymes, overview
-
additional information
-
inhibitor library screening, none selectively targets LoxA over the human LOX isozymes, overview
-
additional information
certain oxazole-4-carbonitrile based LOX inhibitors share a high inhibitory potency for human and mouse ALOX15 but hardly inhibit other mammalian LOX-isoforms
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.1
2-([4-[(4-fluorobenzyl)oxy]butyl]sulfanyl)-5-(naphthalen-1-yl)-1,3,4-oxadiazole
-
Ki above 0.1 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0006
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)butyl)-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.07
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)methyl)-benzyl-4-fluorobenzoate
-
apparent value, Ki above 0.07 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000023
4-(5-(1H-indol-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000057
4-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000043
4-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000081
4-(5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-(5-(3-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.001
4-(5-(furan-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0013
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylamino)but-2-ynyl-thiophene-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0035
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-yn-1-ol
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000076
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-1H-indole-4-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000015
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-benzofuran-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000019
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00014
4-(5-(quinolin-5-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000082
4-(5-(thiophen-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000026
4-(5-phenyl-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00398
4-[(E)-benzoyldiazenyl]benzonitrile
pH and temperature not specified in the publication
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-2-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-3-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0014
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1H-imidazole-4-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2,4-difluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluoropyridine-3-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00047
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-methoxybenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trichlorothiophene-2-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000016
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trifluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4-difluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000027
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-(trifluoromethyl)benzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000031
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chloro-1-benzothiophene-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chlorothiophene-2-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-fluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(difluoromethoxy)benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000033
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(methylsulfonyl)benzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000015
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(triazan-2-yl)benzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethoxy)benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethyl)benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-bromobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-chloro-3-(trifluoromethyl)benzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-[(trifluoromethyl)sulfanyl]benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000085
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclobutanecarboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopentanecarboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00027
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopropanecarboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00017
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl furan-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000022
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl naphthalene-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl thiophene-3-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000026
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]butyl 4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-fluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-chlorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-fluorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-methoxybenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00018 - 0.0011
baicalein
0.001 - 0.009
BODIPY-D3825
0.008
dysidenin
-
above, pH 7.5, recombinant isozyme 15-hLO-1
0.0041 - 0.017
linoleic acid
0.00081
N'-(4-methylphenyl)benzohydrazide
pH and temperature not specified in the publication
0.002
N-(4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol)-2-ylthio)but-2-ynyl-thiophene-2-carboxamide
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.5
neodysidenin
-
above, pH 7.5, recombinant isozyme 15-hLO-1
additional information
additional information
-
0.00018
baicalein
-
-
0.0011
baicalein
-
in the presence of 0.01% Triton X-100
0.001
BODIPY-D3825
-
-
0.0041
linoleic acid
-
-
0.005
linoleic acid
-
fully deuterated, in the presence of 13-(S)-hydroxyoctadecadienoic acid
0.017
linoleic acid
-
fully deuterated
additional information
additional information
-
-
-
additional information
additional information
-
docking experiments and structure activity relationship comparative studies, estimated inhibition constants, calculated in autodock, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.061
(-)-5,7-O-diacetyl-3',4',5'-O-triacetylepigallocatechin-3-O-(3'',4'',5''-O-triacetyl)gallate
Oryctolagus cuniculus
-
IC50: 0.061 mM
0.033
(-)-5,7-O-dibutyryl-3',4',5'-O-tributyrylepigallocatechin-3-O-(3'',4'',5''-O-tributyryl) gallate
Oryctolagus cuniculus
-
IC50: 0.033 mM
0.03
(-)-5,7-O-dimethyl-3',4',5'-O-trimethylepigallocatechin-3-O-(3'',4'',5''-O-trimethyl) gallate
Oryctolagus cuniculus
-
IC50: 0.03 mM
0.031
(-)-5,7-O-dipropionyl-3',4',5'-O-tripropionylepigallocatechin-3-O-(3'',4'',5''-O-tripropionyl) gallate
Oryctolagus cuniculus
-
IC50: 0.031 mM
0.1
(-)-epigallocatechin-3-gallate
Oryctolagus cuniculus
-
IC50: 0.1 mM
0.0014
(-)-jaspic acid
Oryctolagus cuniculus
-
IC50: 0.0014 mM
0.028
1,2,3-triphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.028 mM
0.017
1-(((2,4,6-trimethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.017 mM
0.027
1-(((2,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.027 mM
0.015
1-(((2,5-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.015 mM
0.042
1-(((2-methyl)ethylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.042 mM
0.022
1-(((2-methyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.022 mM
0.021
1-(((2-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.021 mM
0.019
1-(((3,4-dimethoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.019 mM
0.023
1-(((3-thienyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.023 mM
0.016
1-(((4-(2-methylethyl)phenl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.016 mM
0.022
1-(((4-chlorophenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.022 mM
0.025
1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.025 mM
0.025
1-(((4-methoxyphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.025 mM
0.2
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.2 mM
0.22
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.22 mM
0.024
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methoxyphenyl)-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.024 mM
0.2
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.2 mM
0.03
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-dibutyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.03 mM
0.029
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diethyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.029 mM
0.02
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarboxaldehyde
Glycine max
-
IC50: 0.02 mM
0.023
1-(((4-methylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinylethanone
Glycine max
-
IC50: 0.023 mM
0.024
1-(((4-methysulfonyllphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.024 mM
0.023
1-(((4-trifluoromethylphenyl)sulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.023 mM
0.029
1-((4-methylphenyl)sulfonyl)2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.029 mM
0.028
1-((butylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.028 mM
0.022
1-((methylsulfonyl)oxy)-2,3-diphenyl-7-indolizine-carbonitrile
Glycine max
-
IC50: 0.022 mM
0.025
1-((N,N-dimethylaminosulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.025 mM
0.024
1-((phenylsulfonyl)oxy)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.024 mM
0.031
1-(1,3-dibenzyloxy-2-propyloxy)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.031 mM
0.017
1-(1-Hydroxy-1-phenyl-ethyl)-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.017 mM
0.026
1-(1-hydroxyethyl)-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.026 mM
0.024
1-(2-furyl)-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.024 mM
0.02
1-(2-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.02 mM
0.029
1-(2-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.029 mM
0.031
1-(3-chlorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.031 mM
0.02
1-(3-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.02 mM
0.031
1-(4-chlorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.031 mM
0.035
1-(4-fluorophenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.035 mM
0.02 - 0.037
1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
0.032
1-(4-methoxyphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.032 mM
0.037
1-(4-methylphenyl)methoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.037 mM
0.0101
1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.023
1-(Cyclohexyl-hydroxy-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.023 mM
0.022
1-(Hydroxy-p-tolyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.022 mM
0.035 - 0.048
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
0.026
1-(hydroxymethyl)-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.026 mM
0.034
1-(hydroxymethyl)-2,3-diphenylindolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.034 mM
0.021
1-(Methoxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.021 mM
0.031 - 0.075
1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile
0.023 - 0.044
1-acetyl-2,3-diphenylindolizine-7-carbonitrile
0.023 - 0.043
1-benzoyl-2,3-diphenylindolizine-7-carbonitrile
0.027
1-benzyl-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.027 mM
0.027 - 0.039
1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile
0.029 - 0.061
1-formyl-2,3-diphenylindolizine-7-carbonitrile
0.033 - 0.077
1-methoxy-2,3-diphenylindolizine-7-carbonitrile
0.027 - 0.046
1-methyl-2,3-diphenylindolizine-7-carbonitrile
0.00034
1-phenyl-2-([[4-(trifluoromethyl)phenyl]methyl]sulfanyl)-1H-imidazole
Homo sapiens
pH 7.5, 23°C
-
0.031
1-phenylmethoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.031 mM
0.023
1-[(4-Chloro-phenyl)-hydroxy-methyl]-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.023 mM
0.0058
1-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.008
1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.046
1-[4-[4-([[5-(3-chlorophenyl)furan-2-yl]methyl]amino)phenyl]piperazin-1-yl]ethan-1-one
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.0045
1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.017
1-[Hydroxy-(4-methoxy-phenyl)-methyl]-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.017 mM
0.071
11-hydroxytephrosin
Sarcolobus globosus
-
IC50: 0.071 mM
0.018
12alpha-hydroxydeguelin
Sarcolobus globosus
-
IC50: 0.018 mM
0.102
12alpha-hydroxyrotenone
Sarcolobus globosus
-
IC50: 0.102 mM
0.0018 - 0.007
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
0.00079
2,3,4,5-tetrabromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
Homo sapiens
-
IC50: 0.00079 mM
0.0022
2,3,5-tribromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
Homo sapiens
-
IC50: 0.0022 mM
0.033
2,3-bis(4-chlorophenyl)-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.033 mM
0.03
2,3-bis(4-fluorophenyl)-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.03 mM
0.027
2,3-bis(4-methylphenyl)-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.027 mM
0.02
2,3-diphenyl-1-(2-thienyl)indolizine-7-carbonitrile
Glycine max
-
IC50: 0.02 mM
0.019
2,3-diphenyl-1-(3-thienyl)indolizine-7-carbonitrile
Glycine max
-
IC50: 0.019 mM
0.025
2,3-diphenyl-1-indolizinol tosylate
Glycine max
-
IC50: 0.025 mM
0.03 - 0.051
2,3-diphenylindolizine-7-carbonitrile
0.01
2,4-dibromo-6-(2,4-dibromo-6-methoxyphenoxy)phenol
Homo sapiens
-
IC50: 0.01 mM
0.034
2,4-Dibromophenol
Homo sapiens
-
IC50: 0.034 mM
0.005
2,6-dibromo-4-[1-(3-bromo-4-hydroxyphenyl)-1-methylethyl]phenol
Homo sapiens
-
IC50: 0.005 mM
0.0026 - 0.078
2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole
0.034
2-(4-ethylpiperazin-1-yl)4-methylpyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.235
2-(4-ethylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.267
2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.18
2-(4-methylpiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.14
2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.146
2-(piperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.216
2-(pyrrolidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.0067
2-[4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy]-N,N-dimethylethan-1-amine
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.00053
2-[[(4-bromophenyl)methyl]sulfanyl]-1-phenyl-1H-imidazole
Homo sapiens
pH 7.5, 23°C
-
0.00087
2-[[(4-ethylphenyl)methyl]sulfanyl]-1-phenyl-1H-imidazole
Homo sapiens
pH 7.5, 23°C
-
0.0062
3'-chloro-7,8-dihydroxyisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0021
3'-naphthalen-2-yl-1'-phenyl-5-p-tolyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid amide
Glycine max
-
pH 7.4, temperature not specified in the publication
-
0.0015
3'-naphthalen-2-yl-5,1'-diphenyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid amide
Glycine max
-
pH 7.4, temperature not specified in the publication
-
0.00223
3'-naphthalen-2-yl-5,1'-diphenyl-3,4-dihydro-2H,1'H-[3,4']bipyrazole
Glycine max
-
pH 7.4, temperature not specified in the publication
-
0.0009
3,4,6,8-tetrabromooxanthren-1-ol
Homo sapiens
-
IC50: 0.0009 mM
0.005 - 0.009
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
0.011
3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)phenol
Homo sapiens
-
IC50: 0.011 mM
0.015 - 0.05
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
0.0008
3,6,8-tribromooxanthren-1-ol
Homo sapiens
-
IC50: 0.0008 mM
0.00437
3-(4-methoxyphenyl)-5-(3-naphthalen-2-yl-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydro-1,2-oxazole
Glycine max
-
pH 7.4, temperature not specified in the publication
-
0.059
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
0.0031
3-[[(4-methylphenyl)methyl]sulfanyl]-1-phenyl-1H-1,2,4-triazole
Homo sapiens
pH 7.5, 23°C
-
0.00051 - 0.071
4',6,7-trihydroxyisoflavan
0.0038 - 0.1
4',6,7-trihydroxyisoflavanone
0.049
4',6,7-trihydroxyisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0002
4'-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.00053 mM in the presence of arachidonate, IC50: 0.0002 mM in the presence of linoleic acid
0.009
4'-chloro-7,8-dihydroxyisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.00047
4'-ethyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.00026 mM in the presence of arachidonate, IC50: 0.00047 mM in the presence of linoleic acid
0.00023
4'-tert-butyl-N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.00027 mM in the presence of arachidonate, IC50: 0.00023 mM in the presence of linoleic acid
0.011
4,4'-(2,3-dimethylbutane-1,4-diyl)di(benzene-1,2-diol)
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.004
4,4'-propane-2,2-diylbis(2,6-dibromophenol)
Homo sapiens
-
IC50: 0.004 mM
0.062
4,5-bis(4-chlorophenyl)-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.0234
4,5-bis(4-fluorophenyl)-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.0147
4,5-bis(4-methoxyphenyl)-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.000032
4,5-dichloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0152
4,5-diphenyl-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.045 - 0.132
4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
0.0131
4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.055 - 0.378
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
0.036 - 0.133
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
0.0249
4-(4-chlorophenyl)-5-phenyl-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.0137
4-(4-methoxyphenyl)-5-phenyl-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.000017
4-allyl-2-methoxyphenyl 1-adamantanecarboxylate
Glycine max
-
-
0.0022
4-allyl-2-methoxyphenyl 1-cyclohexanecarboxylate
Glycine max
-
-
0.168
4-allyl-2-methoxyphenyl 2-chlorobenzoate
Glycine max
-
-
0.0067
4-allyl-2-methoxyphenyl 2-fluorobenzoate
Glycine max
-
-
0.0772
4-allyl-2-methoxyphenyl 2-methylbenzoate
Glycine max
-
-
0.0333
4-allyl-2-methoxyphenyl 2-pyridinecarboxylate
Glycine max
-
-
0.0052
4-allyl-2-methoxyphenyl 3-chlorobenzoate
Glycine max
-
-
0.0021
4-allyl-2-methoxyphenyl 3-fluorobenzoate
Glycine max
-
-
0.023
4-allyl-2-methoxyphenyl 3-methoxybenzoate
Glycine max
-
-
0.0114
4-allyl-2-methoxyphenyl 3-methylbenzoate
Glycine max
-
-
0.1343
4-allyl-2-methoxyphenyl 4-chlorobenzoate
Glycine max
-
-
0.0072
4-allyl-2-methoxyphenyl 4-fluorobenzoate
Glycine max
-
-
0.019
4-allyl-2-methoxyphenyl 4-methoxybenzoate
Glycine max
-
-
0.0146
4-allyl-2-methoxyphenyl 4-methylbenzoate
Glycine max
-
-
0.0044
4-allyl-2-methoxyphenyl benzoate
Glycine max
-
-
0.0023
4-allyl-2-methoxyphenyl isonicotinate
Glycine max
-
-
0.0017
4-allyl-2-methoxyphenyl nicotinate
Glycine max
-
-
0.048 - 0.055
4-Bromophenol
0.004
4-butyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
Oryctolagus cuniculus
-
IC50: 0.00307 mM in the presence of arachidonate, IC50: 0.004 mM in the presence of linoleic acid
0.014 - 0.05
4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
0.01
4-ethyl-N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide
Oryctolagus cuniculus
-
IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid
0.036
4-methyl-2-(4-ethylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.2
4-methyl-2-(4-hydroxypiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
above, pH 9.0, 20°C
0.018
4-methyl-2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.0171
4-methyl-2-(4-methylpiperazinyl)pyrimido[4,5-b]benzothiazine
Homo sapiens
pH 7.0, 25°C
-
0.076
4-methyl-2-(4-methylpiperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.2
4-methyl-2-(4-phenylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
above, pH 9.0, 20°C
0.053 - 0.058
4-methyl-2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine
0.058
4-methyl-2-(piperidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.048
4-methyl-2-(pyrrolidin-1-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.0046
4-nitrocatechol
Oryctolagus cuniculus
-
IC50: 0.0046 mM
0.000072 - 0.000372
4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide
0.01
4-pentyl-N-[2-(5-phenyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
above, versus substrate linoleic acid
0.00281
4-pentyl-N-[2-(5-phenyl-2-pyrazin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.00097 - 5.321
4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
0.00056
4-pentyl-N-[2-(5-phenyl-2-pyridin-3-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000087 - 3.211
4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
0.000006 - 0.000013
4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
0.000053 - 0.000396
4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide
0.00978
4-[(E)-benzoyldiazenyl]benzonitrile
Homo sapiens
pH and temperature not specified in the publication
0.0094
4-[4-(dimethylamino)phenyl]-5-(4-methoxyphenyl)-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.0057
4-[4-(methylsulfanyl)phenyl]-5-phenyl-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.02
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.00012
5,8,11,14-eicosatetraenoic acid
Oryctolagus cuniculus
-
IC50: 0.00012 mM
0.00157
5-(3,4-dichlorophenyl)-3'-naphthalen-2-yl-1'-phenyl-3,4-dihydro-1'H-[3,4']bipyrazolyl-2-carbothioic acid
Glycine max
-
pH 7.4, temperature not specified in the publication
-
0.00353
5-(3,4-dichlorophenyl)-3'-naphthalen-2-yl-2,1'-diphenyl-3,4-dihydro-2H,1'H-[3,4']-bipyrazole
Glycine max
-
pH 7.4, temperature not specified in the publication
-
0.00423
5-(3-naphthalen-2-yl-1-phenyl-1H-pyrazol-4-yl)-3-p-tolyl-4,5-dihydro-1,2-oxazole
Glycine max
-
pH 7.4, temperature not specified in the publication
-
0.0047
5-(4-chlorophenyl)-4-(4-methoxyphenyl)-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.25
5-(4-chlorophenyl)-4-(4-methoxyphenyl)-2-(methylsulfanyl)-1H-imidazole
Glycine max
-
value above, pH 7.0, temperature not specified in the publication
0.0223
5-(4-chlorophenyl)-4-[4-(dimethylamino)phenyl]-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.0197
5-(4-chlorophenyl)-4-[4-(methylsulfanyl)phenyl]-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.011
5-(4-fluorophenyl)-4-(4-methoxyphenyl)-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.136
5-(4-fluorophenyl)-4-[4-(methylsulfanyl)phenyl]-1H-imidazole-2-thiol
Glycine max
-
pH 7.0, temperature not specified in the publication
0.032 - 0.059
5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine
0.0002
5-(methylamino)-2-(naphthalen-1-yl)-4,5-dihydro-1,3-oxazole-4-carbonitrile
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
-
0.00055
5-chloro-N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
-
0.028
5-ethoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
Glycine max
-
IC50: 0.028 mM
0.029 - 0.059
5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
0.000197
6,6a,11,11a-tetrahydro[1]benzothiopyrano[4,3-b]indole
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
-
0.018
6,7-dihydroxy-2-t-butylbenzopyran-4-one
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.00035 - 0.016
6,7-dihydroxy-3',4'-methylenedioxyisoflavan
0.00021 - 0.0083
6,7-dihydroxy-3'-methylisoflavan
0.00021 - 0.014
6,7-dihydroxy-3'-methylisoflavanone
0.00015 - 0.1
6,7-dihydroxy-4'-methoxyisoflavan
0.0016 - 0.019
6,7-dihydroxy-4'-methoxyisoflavanone
0.137
6,7-dimethoxy-2,3-dihydrochromone
Sarcolobus globosus
-
IC50: 0.137 mM
0.015
6,7-diphenylpyrrolo[1,2-a]pyrimidin-8-ol tosylate
Glycine max
-
IC50: 0.015 mM
0.043
6,7-diphenylpyrrolo[1,2-b]pyridazin-5-yl trifluoromethanesulfonate
Glycine max
-
IC50: 0.043 mM
0.022
6,7-diphenylpyrrolo[1,2-c]pyrimidin-5-ol tosylate
Glycine max
-
IC50: 0.022 mM
0.038
6-hydroxy-2-pentyl-4H-benzopyran-4-one
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0114
6-[4-([1,1'-biphenyl]-2-yl)piperazin-1-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.062
6alpha,12alpha-12alpha-hydroxyelliptone
Sarcolobus globosus
-
IC50: 0.062 mM
0.071
6alpha,12alpha-dehydrodeguelin
Sarcolobus globosus
-
IC50: 0.071 mM
0.1
7,8-dihydroxy-3',4'-dimethoxyisoflavan
0.011
7,8-dihydroxy-3'-methylisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0083
7,8-dihydroxy-3'-trifluoromethylisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0037 - 0.1
7,8-dihydroxy-4'-methoxyisoflavan
0.0057 - 0.1
7,8-dihydroxy-4'-methylisoflavan
0.0078
7,8-dihydroxy-4'-methylisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.013
7,8-dihydroxyisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.022
7-(1,1-dimethylethyl)-2,3-diphenyl-1-indolizinol tosylate
Glycine max
-
IC50: 0.022 mM
0.03
7-cyano-2,3-diphenylindolizin-1-yl 2-methoxybenzoate
Glycine max
-
IC50: 0.03 mM
0.028
7-cyano-2,3-diphenylindolizin-1-yl 3-methoxybenzoate
Glycine max
-
IC50: 0.028 mM
0.028
7-cyano-2,3-diphenylindolizin-1-yl 4-methoxybenzoate
Glycine max
-
IC50: 0.028 mM
0.046 - 0.059
7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate
0.0162
7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.0041
8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.0261
adamantyl caffeate
Homo sapiens
pH 7.0, 25°C
-
0.0031 - 0.05
alpha-mangostin
0.063
barbigerone
Sarcolobus globosus
-
IC50: 0.063 mM
0.027
bestatin
Glycine max
-
IC50: 0.027 mM
0.027
bestatin 7
Homo sapiens
-
IC50: 0.027 mM
0.399
bornyl vanillate
Homo sapiens
pH 7.0, 25°C
-
1
chrysin
Oryctolagus cuniculus
-
IC50: 1 mM
0.00373
dansyl tryptamine
Oryctolagus cuniculus
-
IC50: 0.00373 mM
0.00006
ebselen
Oryctolagus cuniculus
-
i.e. 2-phenyl-1,2-benzisoselenazol-3(2H)-one, irreversible inhibition, IC50: 0.00006 mM
0.06
epicatechin
Oryctolagus cuniculus
-
IC50: 0.06 mM
0.00009
ethyl 6-chloro-3-[(3S)-3-hydroxy-7-methyloctanoyl]-2,3-dihydro-1H-indole-2-carboxylate
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
-
0.011
fenchyl caffeate
Homo sapiens
pH 7.0, 25°C
-
0.167
genistin
Sarcolobus globosus
-
IC50: above 0.167 mM
0.167
glucosyringic acid
Sarcolobus globosus
-
IC50: above 0.167 mM
0.09
hesperetin
Oryctolagus cuniculus
-
IC50: 0.09 mM
0.167
isotachioside
Sarcolobus globosus
-
IC50: above 0.167 mM
0.0003
jaspaquinol
Oryctolagus cuniculus
-
IC50: 0.0003 mM
0.0138
methyl 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.0076 - 0.05
michellamine B
0.00535
N'-(4-methylphenyl)benzohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.031 - 0.186
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
0.08 - 0.822
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
0.038 - 0.375
N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
0.057
N,2-dihydroxybenzamide
Oryctolagus cuniculus
-
IC50: 0.057 mM
0.000099
N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0001
N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.01 - 0.132
N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide
0.003 - 0.75
N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide
0.011 - 0.083
N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide
0.1
N-[(5-bromo-8-hydroxy-5,6,7,8-tetrahydroquinolin-7-yl)(thiophen-2-yl)methyl]acetamide
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.00046
N-[2-(1H-indol-3-yl)ethyl]-2'-methylbiphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.00092 mM in the presence of arachidonate, IC50: 0.00046 mM in the presence of linoleic acid
0.00032
N-[2-(1H-indol-3-yl)ethyl]-3'-methylbiphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.00045 mM in the presence of arachidonate, IC50: 0.00032 mM in the presence of linoleic acid
0.00014
N-[2-(1H-indol-3-yl)ethyl]-4'-(1-methylethyl)biphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.00028 mM in the presence of arachidonate, IC50: 0.00014 mM in the presence of linoleic acid
0.00017
N-[2-(1H-indol-3-yl)ethyl]-4'-(2-methylpropyl)biphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.00091 mM in the presence of arachidonate, IC50: 0.00017 mM in the presence of linoleic acid
0.00109
N-[2-(1H-indol-3-yl)ethyl]-4'-methoxybiphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.0015 mM in the presence of arachidonate, IC50: 0.00109 mM in the presence of linoleic acid
0.00047
N-[2-(1H-indol-3-yl)ethyl]-4'-methylbiphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.00047 mM in the presence of linoleic acid
0.01
N-[2-(1H-indol-3-yl)ethyl]-4-methylbenzenesulfonamide
Oryctolagus cuniculus
-
IC50: 0.01 mM in the presence of arachidonate, IC50: 0.01 mM in the presence of linoleic acid
0.00102
N-[2-(1H-indol-3-yl)ethyl]-4-pentylbenzenesulfonamide
Oryctolagus cuniculus
-
IC50: 0.00042 mM in the presence of arachidonate, IC50: 0.00102 mM in the presence of linoleic acid
0.0032
N-[2-(1H-indol-3-yl)ethyl]-4-propylbenzenesulfonamide
Oryctolagus cuniculus
-
IC50: 0.00313 mM in the presence of arachidonate, IC50: 0.0032 mM in the presence of linoleic acid
0.0042
N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-sulfonamide
Oryctolagus cuniculus
-
IC50: 0.0034 mM in the presence of arachidonate, IC50: 0.0042 mM in the presence of linoleic acid
0.000364 - 0.0028
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-methylbenzenesulfonamide
0.000033 - 0.000162
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
0.01
N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
0.01
N-[2-(2-methyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
above, versus substrate linoleic acid
0.00192 - 0.01
N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
0.00072
N-[2-[2-(2-methyl-1,3-thiazol-4-yl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000099 - 0.0011
N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.000021 - 0.0011
N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.01
N-[2-[2-(4-methoxyphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
above, versus substrate linoleic acid
0.003
N-[2-[2-(4-methylphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000082 - 0.000531
N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.000059 - 0.000261
N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.000014 - 0.00005
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.212 - 3.45
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide
0.083 - 0.719
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
0.272 - 2.41
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
0.091 - 0.646
N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide
0.00014 - 0.000914
N-[3-(2,5-diphenyl-1H-imidazol-4-yl)propyl]-4-pentylbenzenesulfonamide
0.25
naringenin
Oryctolagus cuniculus
-
IC50: 0.25 mM
0.000025
NDGA
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.5
neodysidenin
Homo sapiens
-
above, pH 7.5, recombinant isozyme 15-hLO-1
0.00011 - 0.0018
nordihydroguaiaretic acid
0.00038
PD 146 176
Oryctolagus cuniculus
-
IC50: 0.00038 mM
0.00381
PD-146176
Oryctolagus cuniculus
-
IC50: 0.00381 mM
0.00697
phenyl[(E)-phenyldiazenyl]methanone
Homo sapiens
pH and temperature not specified in the publication
1
rutin
Oryctolagus cuniculus
-
IC50: 1 mM
0.06
sarcolobin
Sarcolobus globosus
-
IC50: 0.06 mM
0.0012
squalene
Prunus persica
-
IC50 is 0.0012 mM
0.0668
stylosin
Homo sapiens
pH 7.0, 25°C
-
0.167
tachioside
Sarcolobus globosus
-
IC50: above 0.167 mM
0.064
tephrosin
Sarcolobus globosus
-
IC50: 0.064 mM
0.16
tert-butylhydroxyanisol
Oryctolagus cuniculus
-
IC50: 0.16 mM
0.017 - 0.028
Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester
0.017 - 0.025
toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester
0.161
vanillic acid 4-O-beta-D-glucoside
Sarcolobus globosus
-
IC50: 0.161 mM
0.1
additional information
Homo sapiens
-
IC50 above 0.1 mM: compound 1a, compound 1b, compound 1d, compound 1e, compound 1g
-
0.02
1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.02 mM
0.037
1-(4-Methoxy-phenyl)-2,3-diphenyl-indolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.037mM
0.035
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
Glycine max
-
IC50: 0.035 mM
0.048
1-(Hydroxy-phenyl-methyl)-2,3-diphenyl-indolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.048 mM
0.031
1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.031 mM
0.075
1-(methoxymethoxy)-2,3-diphenylindolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.075 mM
0.023
1-acetyl-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.023 mM
0.044
1-acetyl-2,3-diphenylindolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.044 mM
0.023
1-benzoyl-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.023 mM
0.043
1-benzoyl-2,3-diphenylindolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.043 mM
0.027
1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile
Glycine max
-
IC50: 0.027 mM
0.039
1-benzyloxymethoxy-2,3-diphenyl-7-indolizinecarbonitrile
Oryctolagus cuniculus
-
IC50: 0.039 mM
0.029
1-formyl-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.029 mM
0.061
1-formyl-2,3-diphenylindolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.061 mM
0.033
1-methoxy-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.033 mM
0.077
1-methoxy-2,3-diphenylindolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.077 mM
0.027
1-methyl-2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.027 mM
0.046
1-methyl-2,3-diphenylindolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.046 mM
0.0018
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
Homo sapiens
-
IC50: 0.0018 mM
0.007
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
Glycine max
-
IC50: 0.007 mM
0.03
2,3-diphenylindolizine-7-carbonitrile
Glycine max
-
IC50: 0.03 mM
0.051
2,3-diphenylindolizine-7-carbonitrile
Oryctolagus cuniculus
-
IC50: 0.051 mM
0.0026
2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole
Homo sapiens
pH 7.5, 23°C
0.078
2-(4-chlorophenyl)-5-cyclohexyl-1,3,4-oxadiazole
Pseudomonas aeruginosa
pH 6.5, 2°C, recombinant His6-tagged enzyme
0.005
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
Homo sapiens
-
IC50: 0.005 mM
0.009
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
Glycine max
-
IC50: 0.009 mM
0.015
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Oryctolagus cuniculus
-
IC50: 0.015 mM
0.05
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Glycine max
-
IC50: 0.05 mM
0.059
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
Homo sapiens
-
IC50: 0.059 mM
0.059
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
Glycine max
-
IC50: 0.059 mM
0.00051
4',6,7-trihydroxyisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.071
4',6,7-trihydroxyisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-2
0.0038
4',6,7-trihydroxyisoflavanone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-2
0.1
4',6,7-trihydroxyisoflavanone
Homo sapiens
-
above, pH 7.5, 22°C, isozyme 15-hLO-1
0.045
4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.132
4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.055
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.378
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.036
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.133
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.048
4-Bromophenol
Glycine max
-
IC50: 0.048 mM
0.055
4-Bromophenol
Homo sapiens
-
IC50: 0.055 mM
0.014
4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.05
4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.053
4-methyl-2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.058
4-methyl-2-(morpholin-4-yl)pyrimido[4,5-b][1,4]benzothiazine
Glycine max
-
pH 9.0, 20°C
0.000072
4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000372
4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.00097
4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
5.321
4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.000087
4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
3.211
4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.000006
4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000013
4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.000053
4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000396
4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.032
5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine
Glycine max
-
IC50: 0.032 mM
0.059
5-(methoxymethoxy)-6,7-diphenylpyrrolo[1,2-b]pyridazine
Oryctolagus cuniculus
-
IC50: 0.059 mM
0.029
5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
Glycine max
-
IC50: 0.029 mM
0.059
5-methoxy-6,7-diphenylpyrrolo[1,2-b]pyridazine
Oryctolagus cuniculus
-
IC50: 0.059 mM
0.00035
6,7-dihydroxy-3',4'-methylenedioxyisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.016
6,7-dihydroxy-3',4'-methylenedioxyisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-2
0.00021
6,7-dihydroxy-3'-methylisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0083
6,7-dihydroxy-3'-methylisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-2
0.00021
6,7-dihydroxy-3'-methylisoflavanone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.014
6,7-dihydroxy-3'-methylisoflavanone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-2
0.00015
6,7-dihydroxy-4'-methoxyisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.1
6,7-dihydroxy-4'-methoxyisoflavan
Homo sapiens
-
above, pH 7.5, 22°C, isozyme 15-hLO-2
0.0016
6,7-dihydroxy-4'-methoxyisoflavanone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-2
0.019
6,7-dihydroxy-4'-methoxyisoflavanone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.1
7,8-dihydroxy-3',4'-dimethoxyisoflavan
Homo sapiens
-
above, pH 7.5, 22°C, isozyme 15-hLO-1
0.1
7,8-dihydroxy-3',4'-dimethoxyisoflavan
Homo sapiens
-
above, pH 7.5, 22°C, isozyme 15-hLO-2
0.0037
7,8-dihydroxy-4'-methoxyisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.1
7,8-dihydroxy-4'-methoxyisoflavan
Homo sapiens
-
above, pH 7.5, 22°C, isozyme 15-hLO-2
0.0057
7,8-dihydroxy-4'-methylisoflavan
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.1
7,8-dihydroxy-4'-methylisoflavan
Homo sapiens
-
above, pH 7.5, 22°C, isozyme 15-hLO-2
0.046
7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate
Glycine max
-
IC50: 0.046 mM
0.059
7-cyano-2,3-diphenylindolizin-1-yl trifluoromethanesulfonate
Oryctolagus cuniculus
-
IC50: 0.059 mM
0.0006
ABT-384
Oryctolagus cuniculus
-
IC50: 0.0006 mM
0.003
ABT-384
Glycine max
-
IC50: 0.003 mM
0.0031
alpha-mangostin
Homo sapiens
-
pH 7.5, recombinant isozyme 15-hLO-1
0.05
alpha-mangostin
Homo sapiens
-
above, pH 7.5, recombinant isozyme 15-hLO-2
0.0003 - 100
apigenin
Homo sapiens
-
IC50: 0.0034 mM without Triton X-100, IC50: 0.0003 mM in the presence of 0.01% Triton X-100
0.18
apigenin
Oryctolagus cuniculus
-
IC50: 0.18 mM
0.5
apigenin
Glycine max
-
IC50: 0.5 mM
0.001
baicalein
Oryctolagus cuniculus
-
IC50: 0.001 mM
0.035
baicalein
Glycine max
-
IC50: 0.035 mM
0.038 - 100
baicalein
Homo sapiens
-
potent inhibitor, IC50: 0.0016 mM without Triton X-100, IC50: 0.038 mM in the presence of 0.01% Triton X-100
0.25
daidzein
Glycine max
-
IC50: 0.25 mM
0.43
daidzein
Oryctolagus cuniculus
-
IC50: 0.43 mM
0.0018
fisetin
Oryctolagus cuniculus
-
IC50: 0.0018 mM
0.0035
fisetin
Glycine max
-
IC50: 0.0035 mM
0.32
flavone
Oryctolagus cuniculus
-
IC50: 0.32 mM
0.7
flavone
Glycine max
-
IC50: 0.7 mM
0.045
galangin
Oryctolagus cuniculus
-
IC50: 0.045 mM
0.2
galangin
Glycine max
-
IC50: 0.2 mM
0.018
genistein
Oryctolagus cuniculus
-
IC50: 0.018 mM
0.167
genistein
Sarcolobus globosus
-
IC50: above 0.167 mM
1
genistein
Glycine max
-
IC50: 1 mM
0.0076
michellamine B
Homo sapiens
-
pH 7.5, recombinant isozyme 15-hLO-1
0.05
michellamine B
Homo sapiens
-
above, pH 7.5, recombinant isozyme 15-hLO-2
0.006
morin
Oryctolagus cuniculus
-
IC50: 0.006 mM
0.018
morin
Glycine max
-
IC50: 0.018 mM
0.006
myricetin
Glycine max
-
IC50: 0.006 mM
0.018
myricetin
Oryctolagus cuniculus
-
IC50: 0.018 mM
0.031
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate linoleic acid
0.186
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate arachidonic acid
0.08
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate linoleic acid
0.822
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate arachidonic acid
0.038
N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate linoleic acid
0.375
N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate arachidonic acid
0.01
N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate linoleic acid
0.132
N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate arachidonic acid
0.003
N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide
Homo sapiens
-
versus substrate linoleic acid
0.75
N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide
Homo sapiens
-
versus substrate arachidonic acid
0.011
N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide
Homo sapiens
-
versus substrate linoleic acid
0.083
N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide
Homo sapiens
-
versus substrate arachidonic acid
0.000364
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-methylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.0028
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-methylbenzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.000033
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000162
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.01
N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
above, versus substrate arachidonic acid
0.01
N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
above, versus substrate linoleic acid
0.00192
N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.01
N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
above, versus substrate arachidonic acid
0.000099
N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.0011
N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.000021
N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.0011
N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.000082
N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000531
N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.000059
N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000261
N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.000014
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.00005
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.212
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide
Homo sapiens
-
versus substrate linoleic acid
3.45
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.083
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate linoleic acid
0.719
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate arachidonic acid
0.272
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate linoleic acid
2.41
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
Homo sapiens
-
versus substrate arachidonic acid
0.091
N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.646
N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.00014
N-[3-(2,5-diphenyl-1H-imidazol-4-yl)propyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000914
N-[3-(2,5-diphenyl-1H-imidazol-4-yl)propyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate arachidonic acid
0.00011
nordihydroguaiaretic acid
Homo sapiens
-
IC50: 0.00011 mM
0.00011
nordihydroguaiaretic acid
Oryctolagus cuniculus
-
IC50: 0.00011 mM
0.0005
nordihydroguaiaretic acid
Oryctolagus cuniculus
-
IC50: 0.0005 mM
0.0018
nordihydroguaiaretic acid
Glycine max
-
IC50: 0.0018 mM
0.0094
NSC172033
Homo sapiens
-
pH 7.5, recombinant isozyme 15-hLO-1
0.05
NSC172033
Homo sapiens
-
above, pH 7.5, recombinant isozyme 15-hLO-2
0.025
NSC292213
Homo sapiens
-
pH 7.5, recombinant isozyme 15-hLO-1
0.05
NSC292213
Homo sapiens
-
above, pH 7.5, recombinant isozyme 15-hLO-2
0.05
NSC617570
Homo sapiens
-
above, pH 7.5, recombinant isozyme 15-hLO-2
0.5
NSC617570
Homo sapiens
-
above, pH 7.5, recombinant isozyme 15-hLO-1
0.004
quercetin
Oryctolagus cuniculus
-
IC50: 0.004 mM
0.0045
quercetin
Glycine max
-
IC50: 0.0045 mM
0.029
quercetin
Sarcolobus globosus
-
IC50: 0.029 mM
0.025
taxifolin
Oryctolagus cuniculus
-
IC50: 0.025 mM
1
taxifolin
Glycine max
-
IC50: 1 mM
0.017
Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester
Glycine max
-
IC50: 0.017 mM
0.028
Toluene-4-sulfonic acid 6,7-diphenyl-pyrrolo[1,2-b]pyridazin-5-yl ester
Oryctolagus cuniculus
-
IC50: 0.028 mM
0.017
toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester
Glycine max
-
IC50: 0.017mM
0.025
toluene-4-sulfonic acid 7-cyano-2,3-diphenyl-indolizin-1-yl ester
Oryctolagus cuniculus
-
IC50: 0.025 mM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
evolution
gene ALOX15 encodes for human 15-LOX type 1 and murine 12/15-LOX. Although the encoded enzymes display slightly different specificities (15- versus 12-lipoxygenating activity), these proteins represent evolutionary and functionally closely-related enzymes that share a high degree of sequence similarity. Of note, these 12/15LOXs that are encoded by the ALOX15 genes have separated from other LOXs early during evolution, although they share close biochemical properties with other LOXs such as ALOX12 or ALOX15B
evolution
gene ALOX15 encodes for human 15-LOX type 1 and murine 12/15-LOX. Although the encoded enzymes display slightly different specificities (15- versus 12-lipoxygenating activity), these proteins represent evolutionary and functionally closely-related enzymes that share a high degree of sequence similarity. Of note, these 12/15LOXs that are encoded by the ALOX15 genes have separated from other LOXs early during evolution, although they share close biochemical properties with other LOXs such as ALOX12 or ALOX15B
evolution
LOX isozymes and classification systems, overview
evolution
LOX isozymes and classification systems, overview
evolution
LOX isozymes and classification systems, overview
evolution
LOX isozymes and classification systems, overview
evolution
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
-
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
H2QBX9
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
-
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
evolution
-
mammals (mice, rats, pigs) express 12-lipoxygenating ALOX15 orthologues. 15-lipoxygenating isoforms are found in primates (orangutans, humans), suggesting an evolution of ALOX15 specificity. Other primates (baboons, rhesus monkeys) express 12-lipoxygenating enzymes. Gibbons, which are flanked in evolution by rhesus monkeys (12-lipoxygenating ALOX15) and orangutans (15-lipoxygenating ALOX15), express an ALOX15 ortholog with pronounced dual specificity, an evolution of ALOX15 specificity, which is aimed at optimizing the biosynthetic capacity for antiinflammatory and proresolving lipoxins. Phylogenetic analysis
malfunction
-
when 15-LOX-1 activity is knocked down by siRNA, the induction of MIP-1alpha, RANTES, and IP-10 is significantly attenuated
malfunction
Alox15 deletion impaired LSC function by affecting cell division and apoptosis, leading to an eventual depletion of leukemia stem cells. Chemical inhibition of enzyme 15-LO function impairs leukemia stem cell function and attenuates chronic myeloid leukemia in mice. The defective chronic myeloid leukemia phenotype in Alox15-deficient animals is rescued by depleting the gene encoding P-selectin, which is upregulated in Alox15-deficient animals. Both deletion and overexpression of P-selectin affects the survival of leukemia stem cells. Loss of Alox15 causes a functional defect in leukemia stem cells
malfunction
deletion of 12/15-LO negates endothelial tight junctions disruption and monocyte adhesion caused by the high-fat diet
malfunction
disruption of normal 12- and 15-LO function by the inflammatory obese condition promotes adipocyte dysfunction and overall metabolic disease including insulin resistance and diabetes
malfunction
streptozotocin (STZ)-induced diabetic mice show upregulated expression of 12/15-LOX and inflammatory cytokines such as tumor necrosis factor (TNF)-alpha and nuclear factor (NF)-kappaB in diabetic hearts. Disruption of 12/15-LOX significantly improves STZ-induced cardiac dysfunction and fibrosis. Deletion of 12/15-LOX inhibits the increases of TNF-alpha and NF-kappaB as well as the production of STZ-induced reactive oxygen species in the heart. Administration of N-acetylcysteine in diabetic mice prevents STZ-induced cardiac fibrosis. Neonatal cultured cardiomyocytes exposed to high glucose conditions induce the expression of 12/15-LOX as well as TNF-alpha, NF-kappaB, and collagen markers. These increases are inhibited by treatment of the 12/15-LOX inhibitor. Disruption of 12/15-LOX reduces inflammation, oxidative stress, and fibrosis in the diabetic heart, thereby improving systolic dysfunction. Disruption of 12/15-LOX decreases cardiac inflammation induced by hyperglycemia
malfunction
-
streptozotocin (STZ)-induced diabetic mice show upregulated expression of 12/15-LOX and inflammatory cytokines such as tumor necrosis factor (TNF)-alpha and nuclear factor (NF)-kappaB in diabetic hearts. Disruption of 12/15-LOX significantly improves STZ-induced cardiac dysfunction and fibrosis. Deletion of 12/15-LOX inhibits the increases of TNF-alpha and NF-kappaB as well as the production of STZ-induced reactive oxygen species in the heart. Administration of N-acetylcysteine in diabetic mice prevents STZ-induced cardiac fibrosis. Neonatal cultured cardiomyocytes exposed to high glucose conditions induce the expression of 12/15-LOX as well as TNF-alpha, NF-kappaB, and collagen markers. These increases are inhibited by treatment of the 12/15-LOX inhibitor. Disruption of 12/15-LOX reduces inflammation, oxidative stress, and fibrosis in the diabetic heart, thereby improving systolic dysfunction. Disruption of 12/15-LOX decreases cardiac inflammation induced by hyperglycemia
-
malfunction
-
deletion of 12/15-LO negates endothelial tight junctions disruption and monocyte adhesion caused by the high-fat diet
-
metabolism
-
shifting linoleic acid metabolism from 15-LOX-1 to COX-2 is procarcinogenic
metabolism
cardiac 12/15-LOX pathway induced by high glucose condition increases the expression of cardiac inflammation in vitro
physiological function
-
12/15-LOX is a critical mediator of the chronic type 1 inflammatory response. Evolution of the immune response to Toxoplasma gondii is accompanied by an increasing requirement for 12/15-LOX mediated signaling. Although 12/15-LOX deficient mice are resistant to acute Toxoplasma gondii infection, 80% of 12/15-LOX-deficient mice die during chronic toxoplasmosis, compared to no deaths in wild-type controls. The enhanced susceptibility of 12/15-LOX-deficient mice to chronic toxoplasmosis is associated with reduced production of IL-12 and gamma interferon (IFN-gamma) that is not evident during acute infection. Ex vivo IFN-gamma production by 12/15-LOX-deficient splenocytes can be rescued by the addition of recombinant IL-12. 12/15-LOX does not play a role in macrophage killing of Toxoplasma gondii in vitro
physiological function
-
12/15LO activity in the vessel wall contributes to atherogenesis by impairing the macrophage ATP-binding cassette transporter G1 cholesterol efflux pathway. 12/15LO activity reduces high density lipoprotein-mediated cholesterol efflux, ATP-binding cassette transporter G1 cellular expression. 12/15LO activity does not affect ATP-binding cassette transporter G1 mRNA expression
physiological function
-
12/15LO expression increases chemokine production. 12/15LO mediates early stages of adipose tissue inflammation and whole body insulin resistance induced by high fat feeding. Adipose tissue from high fat diet-fed 12/15LO KO mice is not infiltrated by macrophages and does not display any increase in the inflammatory markers compared to adipose tissue from normal chow-fed mice. 12/15LO KO mice exhibit no high fat diet-induced change in insulin-stimulated glucose disposal rate or hepatic glucose output. Insulin-stimulated Akt phosphorylation in muscle tissue from high fat diet-fed mice is significantly greater in 12/15LO KO mice than in wild-type mice
physiological function
-
15-lipoxygenases may have chondroprotective properties by reducing metalloproteinase-1 and -13 expression. Their respective metabolites, 13(S)-hydroxy octadecadienoic and 15(S)-hydroxyeicosatetraenoic acids, suppress interleukin-1beta-induced metalloproteinase-1 and -13 expression in a PPARgamma-dependent pathway
physiological function
-
15-LO-1 plays active roles in vascular remodeling, the progression of atherosclerosis and angiogenesis. The PC-3 prostate cancer cell line, which overexpresses 15-LO-1, secretes high levels of vascular endothelial growth factor and enhances tumor growth and angiogenesis as compared with the parental PC-3 cell lines. Angiogenesis and tumor formation is inhibited in transgenic mice overexpressing 15-LO-1 in endothelial cells under the control of preproendothelin promoter. Potential role of 15-LO-1 in regulating endothelium-derived NO, the expression level and activity of 15-LO-1 in endothelial cells may act as a potential NO barometer by modulating the level of eNOS enzyme and bioactive free NO in endothelial cells. 15-LO-1 in human endothelial cells can inhibit angiogenesis and vascular permeability by removing free NO, and its activity can in turn be modulated by the cytoplasmic NO level
physiological function
-
15-LOX metabolites (15(S)-hydroxyeicosatetraenoic acid, 15-hydroxyeicosatrienoic acid or 13(S)-hydroxyoctadecadienoic acid) can inhibit insulin-like growth factor II-induced 12-LOX expression and keratinocytes proliferation
physiological function
-
15-LOX-1 induces chemokine expression in A549 cells. Increased expression and activity of 15-LOX-1 in lung epithelial cells is a proinflammatory event in the pathogenesis of asthma and other inflammatory lung disorders. 15-LOX-1 overexpression results in upregulation of MIP-1alpha, MIP11beta, and RANTES, in increased migration of immature dendritic cells and of activated T cells and increases chemotaxis of mast cells. 15-LOX-1 ectopic expression upregulates NF-kappaB activity
physiological function
-
15-LOX-1 induces phosphorylation of tumor suppressor p53 independent of enzymatic activity. HCT-116 cells transiently transfected with either native or mutant 15-LOX-1 show an increase in p53 phosphorylation and an increase in the expression of downstream genes. 15-LOX-1 interacts with, and binds to, DNA-dependent protein kinase, which causes an approximate 3fold enhancement in kinase activity, resulting in increased p53 phosphorylation at Ser15
physiological function
-
15-LOX-1 promotes mitogenic response to epidermal growth factor in fibroblasts and NaBT-induced apoptosis in colon cancer cells. Non-steroidal anti-inflammatory drugs-induced apoptosis mediated by 15-LOX-1/GATA-6 in colon cancer
physiological function
-
15-LOX-2 increases cell cycle arrest at G0/G1 phase. Injected into athymic nu/nu mice, prostate cancer cells with 15-LOX-2 expression can still form palpable tumors without significant changes in tumorigenicity. But, the tumors with 15-LOX-2 expression grow significantly slower than those derived from vector controls and are kept dormant for a long period of time. Increase in cell death in tumors derived from prostate cancer cells with 15- LOX-2 expression. 15-LOX-2 suppresses vascular endothelial growth factor A gene expression and sustains tumor dormancy in prostate cancer
physiological function
-
endogenous 12/15-LOX defines the resident peritoneal macrophage population and regulates both the recruitment of monocytes/peritoneal macrophage and cytokine response to bacterial products in vivo
physiological function
-
high degree of motional flexibility and a high membrane binding affinity
physiological function
-
high levels of 15LO1 activity can contribute to the increases of MUC5AC observed in asthma
physiological function
-
inhibits tumour growth and metastasis. Enzyme promotes atherosclerosis and can inhibit growth and spread of lung (Lewis lung carcinoma model) and breast (mouse mammary adenocarcinoma model) cancer cells
physiological function
-
is a regulator of angiogenesis, antiangiogenic action in skeletal muscle system. 15-LO-1 significantly decreases all angiogenic effects induced by vascular endothelial growth factor-A and placental growth factor, including capillary perfusion, vascular permeability, vasodilatation, and the increase in capillary number
physiological function
-
lower degree of motional flexibility in aqueous solutions than mammalian isozymes
physiological function
-
macrophages that overexpress 15-LOX-2 show increased secretion of chemokine ligands CXCL10 and CCL2 after 24h incubation. Preconditioned medium from 15-LOX-2-overexpressing cells increases T cell migration, the expression of T cell activation marker CD69 and surface expression of chemokine receptor CXCR3, the CXCL10 chemokine ligand. Increased expression of 15-LOX-2 induced by hypoxia may participate in T cell recruitment in diseases such as atherosclerosis
physiological function
-
overexpression of human 15-LO-1 in RAW macrophages promotes reverse cholesterol transport through increased cholesteryl ester hydrolysis and ABCA1-mediated cholesterol efflux
physiological function
-
pathophysiological role of the enzyme in airway inflammation and atherosclerosis. Role in cell differentiation and importance for maturation of erythrocytes and degradation of cell organells. Role in neoplasia such as prostate cancer and colon carcinoma cells
physiological function
-
pathophysiological role of the enzyme in respiratory inflammation. Mice deficient of 12/15-LO have an attenuated allergic airway inflammation compared to wild type controls
physiological function
-
radiation-induced upregulation of 15-LOX-2 results in significant induction of apoptosis in head-and-neck cancer cells and and enhances killing effect of radiotherapy in head-and-neck cancer. The enzyme inhibits tumor growth through the effect of its main metabolite 15(S)-hydroxyeicosatetranoic acid on PPARgamma signaling pathway
physiological function
-
the expression of 15-lipoxygenase-1 and the putative formation of eoxins by Hodgkin Reed-Sternberg cells in vivo are likely to contribute to the inflammatory features of Hodgkin lymphoma
physiological function
-
high levels of 15LO1 interact with PEBP1 to displace Raf-1 and sustain MAPK/ERK activation
physiological function
12/15-lipoxygenase metabolites of arachidonic acid activate PPARgamma, involvement of 12(S)- and 15(S)-hydroperoxyicosatetraenoate in the regulation of PPARgamma following cerebral ischemia and effects on ischemia-induced inflammatory response. 12(S)-HETE and 15(S)-HETE elicit neuroprotection in rats exposed to focal ischemia. PPARgamma is a member of the nuclear hormone receptorfamily of ligand-dependent transcription factors. PPARgamma regulates genes that are implicated in adipocyte differentiation, lipid and glucose metabolism, and insulin sensitivity
physiological function
12/15-lipoxygenase plays a role in atherosclerosis. 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), the major 12/15-LO metabolite of arachidonic acid, induces endothelial barrier permeability via Src and Pyk2-dependent zonula occluden (ZO)-2 tyrosine phosphorylation and its dissociation from the tight junction complexes. 15(S)-HETE also stimulates macrophage adhesion to the endothelial monolayer in Src and Pyk2-dependent manner. Exposure of arteries from wild-type mice to arachidonate or 15(S)-HETE leads to Src-Pyk2-dependent ZO-2 tyrosine phosphorylation, tight junction disruption, and macrophage adhesion, whereas the arteries from 12/15-LO knock-out mice are protected from these effects of arachidonate. Feeding wild-type mice with a high-fat diet induces the expression of 12/15-LO in the arteries leading to tight junction disruption and macrophage adhesion, and deletion of the 12/15-LO gene disallows these effects. 15(S)-HETE-induced endothelial tight junctions disruption promotes monocyte transmigration, 15(S)-HETE induces the dislocation of both claudin-1 and claudin-5 from ZO-2, that participates in tight junctions
physiological function
12/15-LOX is implicated in the pathogenesis of multiple chronic inflammatory diseases, and its physiologic functions seem to include potent immune modulatory properties that physiologically contribute to the resolution of inflammation and the clearance of inflammation-associated tissue damage. 12/15-LOXs are also involved in the synthesis of lipoxins, which likewise act as anti-inflammatory, pro-resolving mediators. Inflammatory eicosanoids are produced by eosinophils in a 12/15-LOX dependent manner. Docosahexaenoic acid (DHA) is a further substrate of 12/15-LOX. The oxidation of DHA leads to the production of 17S-hydroxy-DHA, an anti-inflammatory mediator, which can be further metabolized into highly active and potent anti-inflammatory resolvins and protectins. 12/15-LOX can metabolize not only free PUFAs, but also PUFAs esterified to membrane-bound phospholipids as well as PUFAs within cholesterol esters. 12/15-LOX-derived mediators as regulators of inflammation, role of 12/15-LOX during inflammation, detailed overview. 12/15-LOX activity in residentmacrophages interferes with theMFG-E8-dependent uptake of apoptotic cells (ACs) by inflammatory, immune-competent phagocytes and thereby fosters the non-immunogenic clearance of ACs, whereas 12/15-LOX-derived lipoxins directly increase the non-inflammatory uptake of dying cells. Possible role of 12/15-LOX in atherosclerosis
physiological function
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
-
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
H2QBX9
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
-
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
-
ALOX15-encoded 12/15-lipoxygenase orthologs are implicated in maturational degradation of intracellular organelles and in the biosynthesis of antiinflammatory and proresolving eicosanoids
physiological function
arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival in a murine model of BCR-ABLinduced chronic myeloid leukemia, in the absence of Alox15, BCRABL is unable to induce CML in mice
physiological function
cardiac 12/15-LOX-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy. 12/15-LOX induces cardiac oxidative stress in the diabetic heart
physiological function
enzyme 15-lipoxygenase is involved in adipose tissue inflammation. The lipoxygenases (LOs) are principal enzymes involved in the oxidative metabolism of polyunsaturated fatty acids, including arachidonic acid. 12- and 15-LO and their lipid metabolites are implicated in the development of insulin resistance and diabetes. Adipose tissue, and in particular visceral adipose tissue, plays a primary role in the development of the inflammation seen in these conditions. 12- and 15-LO and their lipid metabolites act as upstream regulators of many of the cytokines involved in the inflammatory response in adipose tissue. 12- and 15-LO and their lipid metabolites act as upstream regulators of many of the cytokines involved in the inflammatory response in adipose tissue. Significant role for 12- and 15-LO function in white adipose tissue adipogenesis and adipocyte health. 12- and 15-LO function in adipogenesis and has anti-inflammatory roles in adipose tissue, detailed overview. Leukocyte-type 12-LO, or 12/15-LO appears to be a key player in the progression of adipocyte dysfunction and resultant systemic decline. 12/15-LO is upregulated in white adipose tissue in the obese state. Increased expression of all of the 12- and 15-LO enzyme isoforms in omental vs. subcutaneous white adipose tissue suggests that the pathways may contribute to the proinflammatory milieu prominently associated with visceral fat in obesity. The potent vasoconstricting and pro-inflammatory hormone angiotensin II (Ang II) led to increases in leukocyte-type 12-LO mRNA and protein levels, as well as increased enzyme activity
physiological function
enzyme LoxA is a poor catalyst against phosphoester fatty acids, suggesting that LoxA is not involved in membrane decomposition. LoxA also does not react with 5- or 15-HETEs, indicating poor involvement in lipoxin production. The level of LoxA expression is increased when Pseudomonas aeruginosa undergoes the transition to a biofilm mode of growth, but LoxA is not required for biofilm growth on abiotic surfaces. LoxA does appear to be required for biofilm growth in association with the host airway epithelium, suggesting a role for LoxA in mediating bacterium-host interactions during colonization
physiological function
isozyme 15-LOX-2 reaction in intact cells: Ca2+ concentrations in the cell increase in response to stress. The Ca2+ binds to the PLAT domain of 15-LOX-2, resulting in a translocation from the cytosol to the membrane. 15-LOX-2 then binds its substrate arachidonate and oxygenates it to form (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate, 15-HpETE. 15-HpETE is further metabolized by downstream enzymes to form lipoxins, which initiate the resolution of inflammation
physiological function
lipoxygenases (LOX) form a family of lipid peroxidizing enzymes, which are implicated in a number of physiological processes and in the pathogenesis of inflammatory, hyperproliferative and neurodegenerative diseases. Physiological roles of ALOX15, detailed overview
physiological function
lipoxygenases (LOX) form a family of lipid peroxidizing enzymes, which are implicated in a number of physiological processes and in the pathogenesis of inflammatory, hyperproliferative and neurodegenerative diseases. Physiological roles of ALOX15, detailed overview
physiological function
lipoxygenases (LOX) form a family of lipid peroxidizing enzymes, which are implicated in a number of physiological processes and in the pathogenesis of inflammatory, hyperproliferative and neurodegenerative diseases. Physiological roles of ALOX15, detailed overview
physiological function
lipoxygenases (LOX) form a family of lipid peroxidizing enzymes, which are implicated in a number of physiological processes and in the pathogenesis of inflammatory, hyperproliferative and neurodegenerative diseases. Physiological roles of ALOX15, detailed overview
physiological function
roles of arachidonate 15-lipoxygenase in the clearance of dying adipocytes by adipose tissue macrophages, the Alox15 activation in adipose tissue macrophages functions as a mechanism of non-inflammatory removal of dying adipocytes, overview. Alox15 is required for efferocytosis of apoptotic adipocytes by macrophages in vitro. Alox15 can generate peroxisome proliferatoractivated receptor gamma (PPARgamma) ligands, including 13-HODE and 9-HODE in macrophages after CL316243 treatment. Alox15 is required for differentiation of adipocyte progenitors in beta3-adrenergic stimulation-induced adipose tissue remodeling
physiological function
the effects of 15-LOX-generated metabolites of alpha-linolenic acid on lipopolysaccharide-induced inflammation in RAW 264.7 cells and peritoneal macrophages, analysis of the effect of these metabolites on the survival of BALB/c mice in LPS mediated septic shock and also polymicrobial sepsis in Cecal Ligation and Puncture mouse model, overview. Anti-inflammatory effects of 13-(S)-hydroperoxyoctadecatrienoic acid and 13-(S)-hydroxyoctadecatrienoic acid by inactivating NLRP3 inflammasome complex through the PPAR-gama pathway. Both metabolites, especially 13-(S)-hydroperoxyoctadecatrienoic acid, also deactivate autophagy and induce apoptosis
physiological function
12/15-LOX-deficient mice display augmented IL-33-induced lung inflammation, characterized by an increased number of infiltrated eosinophils and group 2 innate lymphoid cells in the airway. The levels of a series of 12/15-LOX-derived metabolites are significantly decreased, and application of 14(S)-hydroxy docosahexaenoic acid suppresses IL-33-mediated eosinophilic inflammation in 12/15-LOX-deficient mice. 14(S)-hydroxy docosahexaenoic acid and 10(S),17(S)-dihydroxy docosahexaenoic acid markedly attenuate ILC2 proliferation and cytokine production at micromolar concentration in vitro
physiological function
15 lipoxygenase 1 is abundant in asthmatic human airway epithelial cells and binds phosphatidylethanolamine-binding protein 1 (PEBP1), leading to generation of hydroperoxy-phospholipids, which drive ferroptotic cell death. 15LO1, PEBP1, and glutathione peroxidase 4 GPX4 activity drives abnormal asthmatic redox biology, to enhance type 2 inflammatory responses. In vitro, type 2 inflammatory cytokine IL-13 induces 15LO1 generation of hydroperoxy-phospholipids, which lowers intracellular GSH and increased extracellular GSSG levels. Lowering GSH further by inhibiting cystine transporter SLC7A11 enhances type 2 inflammatory protein expression and ferroptosis. Ex vivo, redox imbalances correspond to 15LO1 and SLC7A11 expression, type 2 inflammatory biomarkers, and worsen clinical outcomes
physiological function
a sharp increase in protein expression of 12/15 lipoxygenase is found in the pancreatic islets of 10-week old db-/- obese diabetic mice compared to 8-week old counterparts. The increase in islet 12/15 lipoxygenase parallels a decline in islet number. A 2- to 3fold increase especially in 12(S)-hydroperoxytetraeicosanoid acid mirrors the increase in 12/15 lipoxygenase expression in islets. A significant increase of platelet 12/15 lipoxygenase gene expression is found along with 12-hydroperoxytetraeicosanoid acids and 15-hydroperoxytetraeicosanoid acids
physiological function
eosinophil-depleted neutrophils express the 15-lipoxygenase isoform 2 but not the 15-lipoxygenase -1, in contrast to eosinophils which express the 15-lipoxygenase-1 but not the 15-lipoxygenase-2. 15-lipoxygenase metabolite synthesis by neutrophils is not inhibited by the 15-LO-1 inhibitors BLX769, BLX3887, and ML351
physiological function
eosinophils are the major cell type expressing 12/15-LOX during the corneal wound healing process. Eosinophils are recruited into the conjunctiva after corneal epithelium wounding, and eosinophil-deficient and/or eosinophil-specific 12/15-LOX knockout mice show delayed corneal wound healing compared with wild-type mice. A series of 12/15-LOX-derived mediators are significantly decreased in eosinophil-deficient mice and topical application of 17-hydroxydocosahexaenoic acid restores the phenotype
physiological function
eosinophils express the 15-lipoxygenase-1 but not the 15-lipoxygenase-2. The synthesis of 15-lipoxygenase metabolites by neutrophils does not involve the 15-lipoxygenase-1
physiological function
lipoxin B4 is the primary product of 12-LOX and 15-LOX-1 catalysis, if 5S,15S-dihydroperoxyeicosatetraenoic acid is the substrate, with 15-LOX-1 being 20fold more efficient than 12-LOX
physiological function
male Balb/c mice subjected to simulated hypobaric hypoxia for three consecutive days show a robust increase in intra-hippocampal (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate level, which is significantly reduced following baicalein treatment. The elevated level of (5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyeicosa-5,8,10,14-tetraenoate correlates with simultaneous increase in expression of 12/15 LOX in neurons and microglia lining the hippocampal CA3 region. 12/15 LOX gets embedded onto the periphery of mitochondria following hypobaric hypoxia and a strong correlation is observed with loss of mitochondrial integrity
physiological function
-
12/15-lipoxygenase metabolites of arachidonic acid activate PPARgamma, involvement of 12(S)- and 15(S)-hydroperoxyicosatetraenoate in the regulation of PPARgamma following cerebral ischemia and effects on ischemia-induced inflammatory response. 12(S)-HETE and 15(S)-HETE elicit neuroprotection in rats exposed to focal ischemia. PPARgamma is a member of the nuclear hormone receptorfamily of ligand-dependent transcription factors. PPARgamma regulates genes that are implicated in adipocyte differentiation, lipid and glucose metabolism, and insulin sensitivity
-
physiological function
-
the effects of 15-LOX-generated metabolites of alpha-linolenic acid on lipopolysaccharide-induced inflammation in RAW 264.7 cells and peritoneal macrophages, analysis of the effect of these metabolites on the survival of BALB/c mice in LPS mediated septic shock and also polymicrobial sepsis in Cecal Ligation and Puncture mouse model, overview. Anti-inflammatory effects of 13-(S)-hydroperoxyoctadecatrienoic acid and 13-(S)-hydroxyoctadecatrienoic acid by inactivating NLRP3 inflammasome complex through the PPAR-gama pathway. Both metabolites, especially 13-(S)-hydroperoxyoctadecatrienoic acid, also deactivate autophagy and induce apoptosis
-
physiological function
-
12/15-LOX is a critical mediator of the chronic type 1 inflammatory response. Evolution of the immune response to Toxoplasma gondii is accompanied by an increasing requirement for 12/15-LOX mediated signaling. Although 12/15-LOX deficient mice are resistant to acute Toxoplasma gondii infection, 80% of 12/15-LOX-deficient mice die during chronic toxoplasmosis, compared to no deaths in wild-type controls. The enhanced susceptibility of 12/15-LOX-deficient mice to chronic toxoplasmosis is associated with reduced production of IL-12 and gamma interferon (IFN-gamma) that is not evident during acute infection. Ex vivo IFN-gamma production by 12/15-LOX-deficient splenocytes can be rescued by the addition of recombinant IL-12. 12/15-LOX does not play a role in macrophage killing of Toxoplasma gondii in vitro
-
physiological function
-
endogenous 12/15-LOX defines the resident peritoneal macrophage population and regulates both the recruitment of monocytes/peritoneal macrophage and cytokine response to bacterial products in vivo
-
physiological function
-
cardiac 12/15-LOX-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy. 12/15-LOX induces cardiac oxidative stress in the diabetic heart
-
physiological function
-
12/15-lipoxygenase plays a role in atherosclerosis. 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), the major 12/15-LO metabolite of arachidonic acid, induces endothelial barrier permeability via Src and Pyk2-dependent zonula occluden (ZO)-2 tyrosine phosphorylation and its dissociation from the tight junction complexes. 15(S)-HETE also stimulates macrophage adhesion to the endothelial monolayer in Src and Pyk2-dependent manner. Exposure of arteries from wild-type mice to arachidonate or 15(S)-HETE leads to Src-Pyk2-dependent ZO-2 tyrosine phosphorylation, tight junction disruption, and macrophage adhesion, whereas the arteries from 12/15-LO knock-out mice are protected from these effects of arachidonate. Feeding wild-type mice with a high-fat diet induces the expression of 12/15-LO in the arteries leading to tight junction disruption and macrophage adhesion, and deletion of the 12/15-LO gene disallows these effects. 15(S)-HETE-induced endothelial tight junctions disruption promotes monocyte transmigration, 15(S)-HETE induces the dislocation of both claudin-1 and claudin-5 from ZO-2, that participates in tight junctions
-
physiological function
-
12/15LO expression increases chemokine production. 12/15LO mediates early stages of adipose tissue inflammation and whole body insulin resistance induced by high fat feeding. Adipose tissue from high fat diet-fed 12/15LO KO mice is not infiltrated by macrophages and does not display any increase in the inflammatory markers compared to adipose tissue from normal chow-fed mice. 12/15LO KO mice exhibit no high fat diet-induced change in insulin-stimulated glucose disposal rate or hepatic glucose output. Insulin-stimulated Akt phosphorylation in muscle tissue from high fat diet-fed mice is significantly greater in 12/15LO KO mice than in wild-type mice
-
additional information
conformational dynamics of native 15-LOX-2, mass spectrometric analysis, overview
additional information
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
-
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
H2QBX9
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
-
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
-
molecular dynamics simulations and quantum mechanics/molecular mechanics calculations
additional information
quantum mechanics/molecular mechanics calculations with molecular dynamics simulations to study the addition of O2 to the pentadienyl radical of arachidonic acid catalyzed by the Leu597Val and Leu597Ala mutants of rabbit 15-lipoxygenase, detailed overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.